

AI Chatbots and Telemedicine in Cancer Care: Supporting Patients and Enhancing Communications

Authors:

Mohammad-Soroush Khorsand

Azad University Science And Research Branch

Shahin Heidari

University of New Haven

Roya Darbani

Drug Applied Research Center, Tabriz University of
Medical Sciences

Yousef Erfani Karimzadeh Tosi

North Khorasan University of Medical Sciences

Mohammad Hossein Pourasad

Kermanshah University of Medical Sciences

Yasamin Rajabloo

Mashhad University of Medical Sciences

Mahdi Babaei

Isfahan University of Medical Sciences

Shadi Nouri

Arak University of Medical Sciences

Amirali Azimi

Tehran University of Medical Sciences

Fatemeh-sadat Tabatabaei

Tehran University of Medical Sciences

Mina Afra
Nakhchivan State University

Mahtab Mirbolook
Cyprus International University

Mostafa Talebi
Kurdistan University of Medical Sciences

Mohammad Mehdi Atarod
Iran University of Medical Sciences

Maryam Ahmadyan
Shiraz University of Medical Sciences

Sara Zare
Tehran University

Sepideh Hassanpour Khodaei
Eastern Mediterranean University

Shima Moradian-Lotfi
Shahid Beheshti University of Medical Sciences

Amirhossein Esfahani
Mazandaran University of Medical Sciences

Golbarg Saremi
Islamic Azad University of Pharmaceutical Sciences
Branch

Azadeh Bagheri
Islamic Azad University Islamshar Branch

Amirhossein Salmannezhad
Qazvin University of Medical Sciences

Hamed Ghorbani
Islamic Azad University Qazvin Branch

Kamran Sheikhi
Kurdistan University

Mohammad Sabouri
Genova University

Mahrokh Janmohamadi
Iran University of Medical Sciences

Lida Zare Lahijan
University of Tabriz

Behnaz Dalvandi
Islamic azad university,Medical Branch

Reza Dalvandi
Guilan University of Medical Sciences

Seyed Mohammad Shahab Mirabedini
Tehran Azad University

Nasim Razavi
Khorasan University of Medical Sciences

Sara Moghimi
Tulane University

Ahmad Abbaszadeh
Ahvaz Jundishapur University of Medical Sciences

Soroush Najdaghi
Isfahan University of Medical Sciences

Ebrahim Evazi
Hormozgan University of Medical Sciences

Ehsan Ranjbar
Tehran University of Medical Sciences

Delaram Narimani Davani
Isfahan University of Medical Sciences

Morteza Alipour
Universität Hamburg

Mohammad Yahyaei Feriz Hendi
Cleveland State University

Ghazal Sadat Toyserkani
Islamic Azad University of Isfahan, Khorasgan Branch

Mahyar Noorbakhsh
Kashan University of Medical Sciences

DR.MOHAMMAD-SOROUSHKHORSAND

Elham Niknejad

Islamic Azad University of Isfahan, Khorasgan Branch

Ariyan Nazemi

Virginia Tech

Tina Taherzadeh Amlashi

Guilan University of Medical Sciences

Houman Mazaheri

Zanjan University of Medical Sciences

Shamimeh Arabgol

Iran University of Medical Sciences

Amirreza Mohammadnejad

Kurdistan University of Medical Sciences

Maryam Alaei

Shahid Beheshti University of Medical Sciences

Babak Goodarzy

Iran University of Medicine and Sciences

Dorsa Zareie

Tehran Medical Sciences Branch, Islamic Azad University

Hamed Sabzehie

Kocaeli Health and Technology University

Setareh Hedayati Emami

Iran University of Medical Sciences

Roozbeh Roohinezhad

Iran University of Medical Sciences

Yasamin Moradi

The University of North Texas Health Science Center

Parham Heidari

Shiraz University of Medical Sciences

Asal Salehi

Islamic Azad University Tehran Medical Sciences

AI CHATBOTS AND TELEMEDICINE IN CANCER CARE: SU...

Sadegh Bagherzadeh

Tehran University of Medical Sciences

Maryam Azimi

University of Arizona

Mahfam Alijaniha

Zanjan University of Medical Sciences

Sanaz Riahi

University of Oregon

Amirhossein Rigi

Shahid Beheshti university of Medical Sciences

Book Details:

Publisher: Kindle

Publication Date: September 2024

Language: English

Dimensions: 5 x 0.39 x 8 inches

© Kindle and PreferPub 2024

ISBN-13: 979-8339578314

This peer-reviewed book is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specially the rights of translation, reprinting, result of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

Contents

Chapters

1- AI Chatbots and Telemedicine in the Management of Endocrine and Gastrointestinal Cancers

2- AI Chatbots and Telemedicine in the Management of Pediatric Cancers

3- AI Chatbots and Telemedicine in the Management of Skin Cancers

4- AI Chatbots and Telemedicine in the Management of Breast and Lung Cancers

5- AI Chatbots and Telemedicine in the Management of Oral Cancers

6- AI Chatbots and Telemedicine in the Management of Head and Neck Cancers

7- AI Chatbots and Telemedicine in the Management of Urogenital Cancers

8- AI Chatbots and Telemedicine in the Management of Bone Cancers

9- AI Chatbots and Telemedicine in the Management of Other Cancers

1- AI CHATBOTS AND TELEMEDICINE IN THE MANAGEMENT OF ENDOCRINE AND GASTROINTESTINAL CANCERS

Background

AI chatbots and telemedicine play essential roles in the management of endocrine and gastrointestinal diseases by enhancing patient engagement, improving disease monitoring, and facilitating remote care. Their advantages include: Diagnostic support and symptom analysis for early detection;

Educational resources for patient awareness;

Personalized care plans tailored to individual needs;

Remote monitoring for consistent patient engagement and intervention.

These techniques can be further enhanced when coupled with closed-loop drug delivery systems. To understand this integrated system, it's important to first grasp the concept of closed-loop drug delivery.

Closed-loop drug delivery is a system that uses sensors to monitor vital health metrics and autonomously dispenses medication based on those readings. Its goal is to ensure that drug levels

remain within a therapeutic range autonomously, without the need for manual adjustments.

AI chatbots enhance closed-loop drug delivery by analyzing health data in real-time, offering advice for decisions, and facilitating tailored interactions with patients. They can interpret complex health information, which aids in fine-tuning medication amounts and alerting medical professionals about significant changes in a patient's health status.

On the other hand, telemedicine enhances the functionality of closed-loop drug delivery systems by allowing healthcare professionals to monitor and manage treatment remotely. This technology enables doctors to oversee these automated systems, adjust therapeutic approaches, and engage with patients from a distance.

This integrated therapeutic system has recently developed considerably and been implemented in endocrine and gastrointestinal cancers, such as choriocarcinoma, offering several advantages:

1. Precise medication dosage: Real-time adjustments ensure optimal drug levels.
2. Continuous patient support: Chatbots provide information and reminders, enhancing chronic disease management.
3. Wider healthcare reach: Telemedicine facilitates healthcare access for remote patients.
4. Resource efficiency: The system reduces in-person visits, lowering healthcare costs.
5. Customized treatment: Personalized care plans lead to better patient outcomes.

6. Informed decision-making: AI chatbots offer decision support based on complex data analysis.

7. Safety and effectiveness: Automated drug adjustments improve treatment safety and efficacy.

One practical example of this integrated system is CLAUDIA (Closed-Loop Automated Drug Infusion Regulator). Developed by MIT engineers, the CLAUDIA system enhances chemotherapy dosing for gastrointestinal cancer treatment by continuously measuring drug levels during infusion and adjusting the dosage to maintain optimal levels, personalized to the patient's response. In this study, 5-fluorouracil, a common chemotherapy drug for colorectal cancers, was used. This integrated approach with AI chatbots and telemedicine aims to reduce side effects and improve chemotherapy efficacy by ensuring precise drug delivery tailored to individual patient needs.

Another example involves the management of insulinomas, a type of endocrine cancer, using automated insulin delivery (AID) systems. Often referred to as artificial pancreas or closed-loop systems, these systems use continuous glucose monitoring (CGM) to track blood glucose levels and an insulin pump to deliver insulin as needed. The AI chatbot component provides patients with real-time insights into their glucose data, offers recommendations for insulin dosing, and alerts them to potential hypoglycemic events. It

also facilitates communication between patients and healthcare providers, allowing for timely adjustments to treatment plans.

Telemedicine enables remote monitoring of the patient's condition by healthcare professionals, who can access data collected by the AID system, make informed decisions about the patient's care, and communicate changes in treatment directly to the patient.

Gastrointestinal Cancers

The integration of AI chatbots and telemedicine into the management of endocrine and gastrointestinal cancers represents a transformative approach in healthcare. This synergy not only enhances patient outcomes but also streamlines processes, provides continuous support, and offers a more personalized experience for patients. In the evolving landscape of cancer care, these technologies are becoming indispensable tools in the diagnosis, treatment, and ongoing management of endocrine and gastrointestinal cancers.

Artificial Intelligence Chatbots: Enhancing Patient Interaction and Support

AI chatbots have emerged as a revolutionary tool in healthcare, offering numerous benefits in the management of endocrine and gastrointestinal cancers. These digital assistants are designed

to simulate human conversation, providing patients with a range of functionalities, including information dissemination, symptom monitoring, and psychological support. The utilization of natural language processing (NLP) and machine learning (ML) algorithms enables chatbots to understand and respond to patient inquiries accurately and efficiently.

In the context of endocrine cancers, such as thyroid, adrenal, and pancreatic cancers, AI chatbots can assist patients by providing personalized information about their conditions. For instance, patients can inquire about symptoms, treatment options, and side effects, receiving instant and reliable responses based on up-to-date medical knowledge. Chatbots can also offer guidance on lifestyle modifications, such as dietary changes and exercise routines, which are crucial for managing endocrine cancers.

Similarly, in gastrointestinal cancers, including colorectal, stomach, and esophageal cancers, AI chatbots can play a pivotal role. They can educate patients about their conditions, help them understand the importance of early detection, and provide information on screening procedures. Chatbots can also offer support for managing treatment side effects, such as nausea and digestive issues, which are common in gastrointestinal cancer patients.

One of the significant advantages of AI chatbots is their ability to provide 24/7 support. Patients

undergoing cancer treatment often have questions or concerns that arise outside of regular office hours. AI chatbots can bridge this gap, offering continuous assistance and reassurance. This constant availability can help alleviate anxiety and improve overall patient satisfaction.

Telemedicine: Bridging Gaps in Cancer Care

Telemedicine, the practice of providing medical care remotely through digital communication tools, has gained prominence in recent years. It offers a range of benefits for patients with endocrine and gastrointestinal cancers, including increased accessibility, convenience, and continuity of care. Telemedicine platforms enable patients to have virtual consultations with their healthcare providers, reducing the need for in-person visits and minimizing travel-related stress.

For endocrine cancer patients, telemedicine can facilitate regular monitoring and follow-up appointments without the need for frequent hospital visits. For example, patients with thyroid cancer who require regular check-ups and imaging studies can use telemedicine to discuss their results with their oncologists and receive recommendations for further management. This approach can be particularly beneficial for patients living in remote or underserved areas, where access to specialized care may be limited.

In gastrointestinal cancer management, telemedicine can streamline the process of managing complex cases. Patients with colorectal cancer, for instance, can use telemedicine to receive guidance on pre- and post-operative care, discuss symptoms, and adjust their treatment plans based on real-time feedback. Additionally, telemedicine can support the coordination of care among multiple specialists, ensuring a comprehensive and integrated approach to treatment.

The convenience of telemedicine also extends to patient education and support. Virtual platforms can host educational webinars, support groups, and counseling sessions, allowing patients to connect with others undergoing similar experiences and gain valuable information about their conditions. This virtual support network can enhance patient engagement and empowerment, leading to better adherence to treatment plans and improved outcomes.

Synergy of AI Chatbots and Telemedicine

The combination of AI chatbots and telemedicine creates a powerful synergy that can significantly enhance the management of endocrine and gastrointestinal cancers. By integrating chatbots into telemedicine platforms, patients can benefit from a seamless and cohesive care experience. For example, an AI chatbot can

provide initial symptom assessment and triage, directing patients to the appropriate telemedicine consultation based on their needs. This integration can optimize the use of healthcare resources and ensure that patients receive timely and relevant care.

AI chatbots can also complement telemedicine consultations by providing patients with post-appointment follow-up and support. After a virtual consultation, a chatbot can send reminders for medication adherence, follow-up appointments, and lifestyle modifications. It can also answer any additional questions that may arise, ensuring that patients have continuous access to information and guidance.

Moreover, the data collected by AI chatbots during patient interactions can be integrated into telemedicine platforms, providing healthcare providers with valuable insights into patient concerns and needs. This data-driven approach can enhance the personalization of care and support more informed decision-making.

Challenges and Considerations

Despite the promising potential of AI chatbots and telemedicine, several challenges and considerations need to be addressed to optimize their effectiveness in cancer management. One of the primary concerns is ensuring data privacy and security. As these technologies involve the collection and transmission of sensitive patient

information, robust measures must be in place to protect against data breaches and unauthorized access.

Additionally, the accuracy and reliability of AI chatbots are crucial. While these systems are designed to provide accurate information, there is always the potential for errors or misunderstandings. Continuous monitoring and updating of chatbot algorithms are essential to maintain their efficacy and ensure that they provide reliable guidance.

Another consideration is the need for accessibility and inclusivity. Not all patients may have access to the necessary technology or be comfortable using digital tools. Efforts must be made to ensure that these technologies are accessible to all patients, including those with limited technological literacy or disabilities.

Future Directions

The future of AI chatbots and telemedicine in the management of endocrine and gastrointestinal cancers holds great promise. Ongoing advancements in AI and machine learning will continue to enhance the capabilities of chatbots, making them even more effective in supporting patient care. Additionally, the expansion of telemedicine services and the integration of AI into telemedicine platforms will further improve accessibility and convenience for patients.

As these technologies evolve, it will be essential to

conduct ongoing research and evaluation to assess their impact on patient outcomes, satisfaction, and overall healthcare delivery. Collaboration between healthcare providers, technology developers, and patients will be key to optimizing the use of AI chatbots and telemedicine in cancer management.

In conclusion, the integration of AI chatbots and telemedicine represents a significant advancement in the management of endocrine and gastrointestinal cancers. These technologies offer numerous benefits, including enhanced patient support, improved accessibility, and more personalized care. As the field continues to evolve, it is crucial to address the associated challenges and considerations to fully realize the potential of these innovative tools in transforming cancer care.

2- AI CHATBOTS AND TELEMEDICINE IN THE MANAGEMENT OF PEDIATRIC CANCERS

Background

The incorporation of artificial intelligence (AI) chatbots and telemedicine into the management of pediatric cancers represents a paradigm shift in healthcare delivery, offering the potential to enhance patient outcomes. This shift in healthcare delivery could significantly improve outcomes by utilizing AI chatbots and telemedicine in pediatric cancer treatment. As a result, families are relieved of substantial burdens, and the efficiency of care is increased. Recent studies have shed light on the complex implications of this integration, underscoring its potential to drive innovation in pediatric oncology.

In various healthcare domains, particularly in managing chronic conditions and providing mental health support, AI chatbots have shown great promise. These chatbots employ advanced natural language processing (NLP) and machine learning (ML) algorithms to interact effectively with patients. For example, the efficacy of chatbots like "Vivibot," which teach young cancer survivors positive psychology techniques, has

been demonstrated in enhancing post-treatment well-being. Similarly, notable progress in oncology has been made by AI systems such as IBM Watson, which synergistically combines NLP and ML components to provide treatment suggestions that align with doctors' decisions, thereby making cancer management more precise and efficient.

Meanwhile, telemedicine has gained recognition for its capacity to provide follow-up care and medical consultations remotely, which is particularly beneficial for children with complex medical conditions (CMC). By enabling round-the-clock patient monitoring and care, telemedicine eliminates the need for frequent hospital visits, making it a vital tool in pediatric oncology. This not only alleviates the financial and logistical burdens on families but also significantly reduces exposure to hospital-acquired infections like COVID-19.

Studies have shown that telemedicine effectively reduces unplanned hospitalizations and healthcare costs while increasing caregiver satisfaction. For instance, specialized telemedicine systems have been reported to enhance CMC management by supporting home care and decreasing the need for emergency interventions. Additionally, mobile health (mHealth) interventions have demonstrated positive impacts on chronic disease outcomes, suggesting that similar strategies could benefit pediatric oncology. In low- and middle-income

countries, mHealth has been found to improve clinical outcomes and health-related quality of life (HRQoL).

Moreover, telemedicine combined with AI chatbots provides a synergistic approach to pediatric cancer treatment. AI chatbots can offer continuous patient engagement, symptom monitoring, educational materials, and mental health support. For example, they can schedule appointments, provide psychosocial support, and guide patients and their families through treatment protocols, enhancing the overall quality of care. Telemedicine platforms that integrate AI can also improve the efficiency of data collection and analysis, enabling medical staff to access real-time patient health information. This facilitates early intervention and individualized care plans, offering personalized, accessible support throughout the treatment course. Together, these technologies have the potential to revolutionize pediatric cancer care.

Despite their promising potential, the widespread use of AI chatbots and telemedicine in pediatric oncology still faces challenges. Critical considerations include data privacy, the need for robust regulatory frameworks, and ensuring equitable access to technology. Additionally, ongoing research is essential to assess the long-term safety and effectiveness of these technologies across diverse populations. Addressing these concerns will be key to realizing the full benefits

of AI and telemedicine in pediatric cancer management.

Understanding the Role of AI Chatbots

AI chatbots have emerged as powerful tools in various domains of healthcare, including the management of pediatric cancers. These digital assistants use natural language processing (NLP) and machine learning algorithms to interact with patients and their families, providing timely information and support. In the context of pediatric oncology, chatbots serve several crucial functions.

One of the primary roles of AI chatbots is to offer information and education about pediatric cancers. Parents and caregivers often face a steep learning curve when dealing with a child's cancer diagnosis. AI chatbots can provide answers to common questions about specific types of cancers, treatment options, and potential side effects. This information is crucial in helping families understand their child's condition and make informed decisions about their care.

AI chatbots can also play a role in symptom management and monitoring. For instance, they can assist in tracking symptoms and side effects reported by patients and provide guidance on how to manage these symptoms. By continuously collecting and analyzing data, chatbots can offer insights into the patient's condition and alert

healthcare providers if any concerning patterns emerge. This proactive approach can lead to early intervention and adjustments in treatment, potentially improving outcomes.

Furthermore, AI chatbots can support emotional and psychological well-being. A cancer diagnosis can be overwhelming for both the patient and their family. Chatbots can offer emotional support, provide coping strategies, and connect users with additional resources such as counseling services or support groups. This aspect of care is often overlooked but is vital for the overall well-being of young patients and their families.

Telemedicine: Expanding Access and Improving Care

Telemedicine, which involves providing medical care remotely using digital communication tools, has revolutionized how healthcare services are delivered. In pediatric oncology, telemedicine offers several key benefits, including increased accessibility, reduced travel burdens, and continuity of care.

For families living in remote or underserved areas, access to specialized cancer care can be a significant challenge. Telemedicine bridges this gap by enabling virtual consultations with oncologists and other specialists. This means that families do not need to travel long distances for regular check-ups or follow-up appointments. Instead, they can receive care from the comfort of

their home, which can be particularly beneficial for children undergoing treatment.

In addition to reducing travel-related stress, telemedicine facilitates more frequent and convenient interactions between patients and healthcare providers. For example, telemedicine platforms can be used for routine monitoring, discussing treatment plans, and addressing any concerns or side effects. This continuous connection can lead to better management of the child's condition and more personalized care.

Telemedicine also supports the coordination of care among multiple specialists. Pediatric cancer care often involves a multidisciplinary team, including oncologists, surgeons, radiologists, and other healthcare professionals. Telemedicine enables these specialists to collaborate more effectively, ensuring that all aspects of the patient's care are coordinated and optimized.

Integrating AI Chatbots and Telemedicine

The integration of AI chatbots and telemedicine creates a synergistic approach to managing pediatric cancers. By combining these technologies, healthcare providers can offer a more comprehensive and efficient care experience. For instance, AI chatbots can be integrated into telemedicine platforms to provide patients and families with immediate assistance before, during, and after virtual consultations. A chatbot

can handle routine inquiries, provide educational resources, and assist with appointment scheduling, allowing healthcare providers to focus on more complex tasks during consultations.

Moreover, AI chatbots can help with the pre-consultation process by gathering relevant information from patients and families. This information can be used to prepare for the virtual consultation, ensuring that the healthcare provider has all the necessary details to make informed decisions. This streamlined approach can lead to more efficient and effective consultations.

Post-consultation, chatbots can provide follow-up support, such as reminding patients about medication schedules, monitoring symptoms, and addressing any additional questions or concerns. This continuous support can enhance patient engagement and adherence to treatment plans.

Challenges and Considerations

While the integration of AI chatbots and telemedicine offers numerous benefits, there are several challenges and considerations that must be addressed to ensure their effective implementation in pediatric cancer care.

One of the primary concerns is ensuring data privacy and security. AI chatbots and telemedicine platforms handle sensitive patient information, and it is crucial to protect this data from unauthorized access and breaches. Robust security

measures, including encryption and secure authentication, are essential to safeguarding patient information.

Another challenge is ensuring that these technologies are accessible to all patients and families. Not all families may have access to the necessary technology or internet connectivity to use telemedicine services effectively. Additionally, some patients and families may have varying levels of comfort with digital tools. It is important to provide support and alternatives for those who may face barriers to using these technologies.

The accuracy and reliability of AI chatbots also pose a concern. While chatbots can provide valuable information and support, there is always the risk of errors or misunderstandings. Continuous monitoring and updating of chatbot algorithms are necessary to ensure that they provide accurate and relevant information.

Future Directions

The future of AI chatbots and telemedicine in the management of pediatric cancers holds exciting possibilities. As technology continues to advance, these tools are likely to become even more integrated into routine cancer care.

One area of future development is the enhancement of AI chatbot capabilities. Advances in natural language processing and machine learning will enable chatbots to provide even more personalized and accurate support. For example,

future chatbots may be able to analyze patient data in real-time to offer tailored recommendations and alerts.

Telemedicine platforms will also continue to evolve, offering more advanced features and capabilities. Integration with wearable devices and remote monitoring tools could provide real-time data on patient health, allowing for more proactive management of pediatric cancers.

Additionally, ongoing research and evaluation will be crucial in assessing the impact of these technologies on patient outcomes and healthcare delivery. Studies will help determine the effectiveness of AI chatbots and telemedicine in improving care, patient satisfaction, and overall quality of life for young cancer patients.

Conclusion

AI chatbots and telemedicine represent significant advancements in the management of pediatric cancers. By enhancing patient support, improving access to care, and offering continuous monitoring, these technologies are transforming how pediatric cancer care is delivered. While there are challenges to address, the potential benefits of AI chatbots and telemedicine are substantial. As technology continues to evolve, these tools will play an increasingly important role in providing personalized, efficient, and compassionate care for children with cancer and their families.

3- AI CHATBOTS AND TELEMEDICINE IN THE MANAGEMENT OF SKIN CANCERS

Background

The healthcare industry has been transformed by artificial intelligence (AI) through innovations such as AI chatbots and telemedicine, which offer new methods for patient management and care. AI chatbots are computer programs that mimic human speech patterns using natural language processing, while telemedicine enables healthcare providers to deliver medical services remotely via telecommunication technology. The integration of AI chatbots and telemedicine into skin cancer management holds great promise for improving patient outcomes and streamlining healthcare. This technology facilitates early detection and management of skin lesions, provides personalized patient education and support, enables remote consultations with dermatologists, and enhances the overall efficiency of skin cancer care. By leveraging AI chatbots and telemedicine, healthcare providers can extend their reach to underserved populations, optimizing and personalizing products used in skin cancer management.

Review Search Criteria and Aim

In this review, we included only articles related to the telemedicine and AI chatbot approaches in the management of skin cancer. Initially, we retrieved 349,783 articles (Telemedicine: 61,787; Skin cancer: 287,505; AI chatbots: 491). After a second screening, we included 20 articles and some reviews pertinent to telemedicine and AI chatbots in skin cancer management. Among these, 459 articles were related to both telemedicine and skin cancer, while 3 were related to both AI chatbots and skin cancer.

AI Chatbots and Telemedicine in Skin Cancer Management

Description and Capabilities of AI Chatbots

AI chatbots are computer programs that use artificial intelligence and natural language processing to simulate human conversations. These chatbots can understand and respond to user inquiries, providing information, guidance, and support related to skin cancer management. They can be integrated into websites, mobile applications, and messaging services, making them accessible to patients.

AI chatbots offer several valuable capabilities in skin cancer management. They can educate patients about skin cancer prevention, risk factors,

and self-screening strategies. They also assist in diagnosing skin lesions by guiding users through diagnostic tools and recommending further investigation. Furthermore, AI chatbots support patients undergoing treatment by offering resources, follow-up appointment reminders, and medication adherence aids.

Benefits of Using AI Chatbots in Skin Cancer Management

The use of AI chatbots in skin cancer management presents numerous benefits for patients and healthcare providers:

Enhanced Healthcare Accessibility: Patients can access information and support for managing skin cancer anytime and anywhere using AI chatbots.

Improved Patient Responsiveness: Virtual assistants equipped with AI can interact with patients to deliver personalized advice and educational materials, enhancing patient understanding of how to manage their skin health.

Early Detection Requirements: AI-powered chatbots can guide users through self-assessment tools to identify suspicious skin lesions and recommend seeking further evaluation.

Efficient Triage and Resource Allocation: AI chatbots can prioritize patients based on the urgency of their condition, providing an initial assessment and guiding healthcare providers. This ensures prompt attention to serious cases and

optimal use of resources.

Examples of Existing AI Chatbot Applications in Dermatology

Several AI-powered chatbot applications are already used in dermatology for managing skin cancer:

SkinVision: A mobile application that uses AI algorithms to analyze photos of skin lesions and provide risk assessments for skin cancer. It guides users through a process to monitor changes in their skin over time.

Ada: An AI-based conversational agent that offers personalized health checkups based on user input. It helps identify possible signs of skin neoplasms and directs users to appropriate laboratory examinations.

Buoy Health: An AI chatbot that employs machine learning models to assist users in describing symptoms and clarifying when to seek medical advice.

Telemedicine in the Management of Skin Cancer

Explanation and Definition of Telemedicine

Telemedicine involves the use of telecommunication technologies to provide remote medical services. It encompasses the exchange of medical information and the

provision of clinical services using audio, video, and other communication tools. In skin cancer management, telemedicine typically involves video consultations, remote monitoring, and digital image analysis. These tools help dermatologists and other medical practitioners assess skin problems, provide self-examination guidance, and monitor treatment progress from a distance.

Advantages of Telemedicine in Skin Cancer Management

The benefits of using telemedicine for managing skin cancer include:

Better Access to Specialized Care: Telemedicine removes geographical barriers, enabling individuals in remote areas with limited access to dermatological services to receive specialized care.

Time and Cost Savings: Telemedicine reduces the need for patients to travel to healthcare facilities, saving time and transportation costs while improving resource allocation for healthcare providers.

Early Detection: Telemedicine allows patients to send pictures or videos of abnormal skin growths to healthcare providers, facilitating early detection of skin cancers.

Ongoing Patient Follow-Up: Telemedicine ensures that patients can continue follow-up care with their doctors without the need for physical visits, leading to improved health outcomes and timely

intervention.

Examples of Successful Telemedicine Programs for Skin Cancer

Teledermatology Program at the University of California, San Francisco (UCSF): This program offers remote dermatology consultations for patients suspected of having skin cancer. Patients can send pictures of their skin lesions via a secure online platform, and dermatologists provide diagnoses and treatment recommendations. The program has reduced wait times for skin disorder consultations and achieved high patient satisfaction.

TeleDermatology Program of the Veterans Health Administration (VHA): This program uses telemedicine to deliver dermatology consultations to veterans across the US. Patients upload images of their skin lesions through a secure portal, and dermatologists analyze them remotely to suggest diagnoses and treatments. This program has improved access to dermatological care for veterans in rural areas, eliminating wait times and enhancing convenience.

Challenges and Limitations of Implementing AI Chatbots and Telemedicine in Skin Cancer Management

Accurate Detection

There is uncertainty regarding whether accurate detections can be attributed solely to the quality of algorithms used by AI chatbots. If this claim is valid, further research is necessary before drawing definitive conclusions about their effectiveness.

Legal and Ethical Considerations

The use of AI chatbots raises significant concerns about patient privacy, liability, and the reliability of machines in medical decision-making. Clear guidelines and regulations are essential to address these issues and ensure that AI chatbots are used responsibly.

User Acceptance and Trust

Patients may be hesitant to rely entirely on AI chatbots. Building trust among patients, healthcare providers, and AI chatbot systems is crucial for the successful implementation of these technologies.

Future Directions and Implications

Potential Advancements and Innovations

AI chatbots and telemedicine are poised to make significant contributions to skin cancer management in the future. Several potential

advancements could enhance the roles of these technologies. AI chatbots may improve their diagnostic accuracy and offer personalized advice, leading to better prognoses and reduced mortality rates. Integrating machine learning algorithms into AI chatbots could refine their recommendations by analyzing extensive datasets on skin cancer incidences and historical medical documents.

Additionally, wearable devices capable of capturing high-resolution images of skin lesions could be developed. These devices, when combined with AI chatbots, would enable patients to take and send images of skin abnormalities for immediate feedback on potential malignancy. This approach would allow patients to monitor their skin health more closely and seek professional help when necessary.

Expanding telemedicine platforms to include virtual dermatology consultations could address the shortage of dermatologists in many areas. Video consultations would enable dermatologists to assess skin lesions remotely and provide recommendations for further evaluation or treatment, thereby improving access to specialized care in remote locations.

Ethical Considerations and Patient Acceptance

While the potential benefits of AI chatbots and telemedicine in skin cancer management are

considerable, ethical issues must be addressed. Patient data privacy and security are critical concerns, especially when transmitted over telemedicine platforms. It is imperative that healthcare providers and policymakers implement stringent security measures to protect patient information.

Patient reactions to AI chatbots and telemedicine may vary. Some patients may prefer in-person consultations with their doctors, while others may embrace the convenience of telemedicine services. Engaging both groups in the development and implementation of these technologies is essential to address their concerns and meet their needs.

Recommendations for Healthcare Providers and Policymakers

Healthcare providers and policymakers should consider the following recommendations to fully realize the benefits of AI chatbots and telemedicine in skin cancer management:

Public Education: Inform the public about AI and its role in skin cancer management to help individuals make informed healthcare choices.

Regulations: Establish state regulations to ensure that AI chatbots and telemedicine technologies are used safely and ethically.

Collaboration: Foster collaboration between healthcare providers, technology developers, and policymakers to create common standards for

integrating AI chatbots and telemedicine into existing healthcare systems.

Cost-Effectiveness: Evaluate the cost-effectiveness of AI chatbots and telemedicine to guide equitable resource distribution and ensure fair access to these technologies.

In summary, AI-driven chatbots and telemedicine have the potential to revolutionize skin cancer management. With continued technological advancements and careful consideration of ethical issues, these tools could lead to earlier detection, improved patient survival rates, and easier access to specialized care. Implementing the above recommendations will help establish a future where AI chatbots and telemedicine are integral to managing skin diseases.

Discussion and Conclusion

Summary of Key Points

AI chatbots offer significant benefits in skin cancer management by providing timely and accurate information, while telemedicine technologies facilitate remote monitoring and communication regarding skin lesions. This review highlighted the advantages of AI chatbots and telemedicine, including early detection of skin cancers, personalized recommendations, and enhanced access to expert care. Potential advancements, such as integrating machine learning algorithms and wearable devices, could further improve

these technologies. Addressing ethical concerns and ensuring patient acceptance are crucial for maximizing the benefits of AI chatbots and telemedicine.

***Importance of Further
Research and Development***

Further research and development are essential to assess the reliability and economic feasibility of AI chatbots for diagnosing skin cancer. Studies should also explore patient satisfaction and address ethical considerations associated with the use of AI chatbots and telemedicine. Advancements in this field could lead to improved detection rates, better patient outcomes, and broader access to medical specialists. Continued collaboration among healthcare providers, researchers, and policymakers will be vital for the successful integration of these technologies into clinical practice.

4- AI CHATBOTS AND TELEMEDICINE IN THE MANAGEMENT OF BREAST AND LUNG CANCERS

Background

Over the past decades, significant efforts have been made to leverage artificial intelligence (AI) in medicine and healthcare. AI, initiated in the 1950s, encompasses subfields such as knowledge representation, machine learning (ML), and natural language processing (NLP). ML utilizes algorithms to analyze large datasets and make decisions, while deep learning (DL) employs artificial neural networks with multiple layers to enable independent learning. NLP, combining computational linguistics and ML, allows computers to understand human text. In medicine, AI chatbots powered by NLP are notable for simulating human conversations, with applications in remote patient monitoring, emotional support, lifestyle coaching, and treatment planning. The advent of DL in NLP has led to breakthroughs such as large language models (LLMs), which can generate new content and adapt to various domains with minimal examples. ChatGPT and other LLM-based chatbots, like Google BARD and Anthropic Claude, have

demonstrated versatility across different tasks, prompting studies to explore their potential in healthcare and oncology.

Breast and lung cancers, two of the leading causes of cancer-related deaths worldwide, pose a significant threat to global health. Early diagnosis and timely treatment are critical for improving patient survival. However, access to quality healthcare, particularly in underserved and remote areas, remains a persistent challenge. AI chatbots, intelligent computer programs capable of conversing with humans, are emerging as transformative tools in cancer screening and management, playing a multifaceted role in enhancing patient outcomes.

AI chatbots are positioned to revolutionize the early detection of breast and lung cancers by enabling individuals to take a more proactive role in their health. These intelligent programs act as virtual health educators, providing clear and accessible information about the warning signs of these cancers. Beyond simple awareness campaigns, chatbots can administer online screening questionnaires that assess individual risk factors and guide users toward seeking medical attention if concerning symptoms are identified. Moreover, chatbots can be integrated with advanced algorithms to assist in the preliminary analysis of screening results, such as mammograms or chest CT scans. This integration can involve highlighting potential abnormalities

and prompting users to schedule follow-up appointments or additional testing with qualified healthcare professionals. Ultimately, chatbots serve as a vital bridge between public awareness campaigns and definitive medical interventions, potentially leading to earlier diagnoses and better patient outcomes.

AI chatbots are also transforming the way patients navigate the complexities of cancer treatment. These virtual assistants can empower patients by simplifying intricate treatment plans. For instance, a chatbot could break down chemotherapy or radiation therapy schedules into clear, easy-to-understand steps, complete with medication reminders and strategies for managing potential side effects. Beyond medication management, chatbots can connect patients with valuable support systems, serving as digital bridges to online support groups, counseling services, and information on patient rights and financial assistance programs. This holistic approach goes beyond simply providing information—chatbots foster a sense of community and emotional well-being during a challenging time. Additionally, chatbots play a crucial role in medical research by facilitating data collection from patients. By gathering information on symptoms, side effects, and individual responses to treatment, chatbots contribute to a vast pool of anonymized data that researchers can use to refine existing therapies

and develop more effective treatment options for the future. In essence, chatbots are evolving into powerful allies for patients, providing knowledge, support, and the ability to contribute to advancements in cancer care.

AI chatbots are becoming powerful democratizing forces in the fight against cancer. They help bridge the gap in access to care, particularly for individuals in remote or underserved areas who may struggle to reach traditional screening services. By providing easily digestible information on breast and lung cancer warning signs in multiple languages and cultural contexts, chatbots empower individuals to become active participants in their own health. This can include offering interactive educational modules and self-assessment tools that raise awareness and encourage regular screenings. The readily accessible nature of chatbots can significantly boost screening rates, potentially leading to earlier diagnoses and improved patient survival rates. The benefits of chatbots extend beyond initial detection. They can serve as virtual navigators throughout the entire cancer care journey. For instance, a chatbot could translate complex medical jargon into clear, understandable language, helping patients comprehend and manage their treatment plans. This can include assistance with scheduling, medication reminders, and strategies for managing side effects. Moreover, chatbots can connect patients

with vital support networks, fostering emotional well-being and a sense of community. Finally, chatbots can alleviate the burden on healthcare providers by acting as the first line of defense for basic inquiries and initial information dissemination. This allows medical professionals to focus on more complex cases and deliver personalized patient care. In essence, chatbots are evolving from simple information providers into holistic healthcare companions, empowering individuals, streamlining processes, and ultimately contributing to a future with improved cancer outcomes for all.

While AI chatbots hold immense promise, it is crucial to address certain challenges to ensure their responsible and effective use in healthcare. One primary concern is the accuracy and timeliness of the information provided by chatbots. Constant updates are essential to ensure that chatbots reflect the latest medical knowledge on cancer symptoms, screening guidelines, treatment options, and potential side effects. Furthermore, robust data security measures are paramount to protect patient privacy during chatbot interactions. It is important to recognize that chatbots are not substitutes for qualified medical professionals. They cannot provide expert advice, perform complex diagnoses, or make personalized treatment recommendations. Instead, they should function as complementary tools, empowering patients with information,

facilitating communication, and streamlining access to care, while healthcare professionals continue to provide the irreplaceable expertise and human touch in diagnosis and treatment. If a chatbot identifies potential risk factors or abnormal results, it should always direct individuals to seek medical attention from a doctor or another qualified healthcare provider for proper diagnosis and treatment planning.

Artificial Intelligence (AI) is a broad concept and an advanced field of study that integrates statistical methodologies, application systems, and big data in medical imaging. With the advent of image recognition and deep learning, AI can now perform specific computer vision tasks in healthcare applications, including medical imaging.

Since the COVID-19 pandemic, there has been a surge in the use of telemedicine to deliver healthcare remotely, providing an effective means of reducing exposure risks. Although telemedicine helps overcome geographical boundaries, improve health outcomes, increase convenience, and reduce costs, especially in rural areas, several limitations have been reported, such as inconsistent coverage, access disparities, and infrastructure deprivation. Historically, telemedicine has taken on two forms: video communications and telephone visits. However, more recently, multiple virtual communication platforms have been implemented. One of the

most commonly used services of telemedicine is telerehabilitation, which has been utilized to enhance treatment adherence and achieve intervention goals.

Among the various AI-based tools is the AI chatbot. Chatbots, or embodied conversational agents, are software applications that conduct dialogue systems using human interaction patterns to perform tasks. These conversational agents can assist users through pointing, speaking, and visual interfaces. They also have applications in healthcare services, including predicting hospital discharge, diagnosing infections like sexually transmitted infections (STIs), providing post-hospitalization care, and aiding in stress management.

Lung diseases account for approximately 17% of deaths worldwide, making them among the deadliest global health concerns. Lung cancer, in particular, caused 1.8 million deaths in 2020, representing a major cause of cancer-related mortality. Lung cancers are divided into two main histological subtypes: non-small cell lung cancer (NSCLC), the most common subtype with adenocarcinoma being the most predominant, and small cell lung cancer, the most aggressive form with the highest mortality rate.

Histopathologic confirmation remains the definitive method for characterizing and diagnosing lung disease. However, emerging evidence in medical imaging over the last

decade has shown that medical images provide complementary data to pathology. The development of various AI-based applications has introduced significant advances in lung cancer diagnostics, prognosis, and monitoring treatment responses. Currently, most ongoing AI applications focus on lung cancers and nodule detection.

Breast cancer is another major global health concern, often leading to high morbidity and being a predominant cause of cancer-related mortality. Recent data from 2020 estimated an incidence rate of 2.3 million new cases and a five-year prevalence rate of 7.8 million women. Breast cancer is a heterogeneous group of diseases with diverse biological subtypes, each with different clinicopathological features and molecular profiles. While various treatment methods, including chemotherapy, radiation therapy, and surgical removal, have been proposed, these options often impose significant emotional, social, and physical costs.

New treatment options require thorough diagnostic stratification and innovative communication methods. The former primarily involves a detailed, highly variable, and time-consuming manual review of pathology slides. Historically, communication was based on direct, face-to-face visits. However, computer-based digitization offers reduced variability in assessment and improved reliability in diagnostic

stratification. Meanwhile, telemedicine provides a path to higher patient satisfaction and a lower symptom burden.

Chatbots and AI applications in telemedicine are advancing the field of medicine by automating healthcare processes. Telemedicine has become a valuable tool for improving efficiency and accessibility in managing respiratory diseases, enabling physicians and patients to interact remotely. This reduces the risk of disease transmission and facilitates access to medical care in areas with limited mobility. Telemedicine enhances healthcare service delivery by allowing patients to conduct medical consultations remotely, improving diagnosis, real-time monitoring, and treatment efficiency.

Chatbots, which can be categorized into paid and free versions, inform patients to seek medical attention based on their responses and symptoms. These digital assistants utilize natural language processing to understand user inquiries and provide recommendations for testing. By leveraging machine learning algorithms, chatbots can analyze data to identify patterns that aid in earlier disease detection. However, the accuracy of chatbots is contingent upon the quantity and quality of training data, necessitating further development and research to fully harness their potential in disease management.

Chatbots also face limitations that could

potentially impact users, such as concerns about cybersecurity, accuracy, technological maturity, and a lack of empathy, which may contribute to delays in their integration and acceptability within healthcare systems.

Chatbots function as digital assistants, enabling users to communicate their needs, questions, and interests through voice, typing, or other inputs. They can be implemented through websites, mobile apps, or telephone messaging applications. Examples of voice-based chatbots include Siri (Apple), Google Now (Google), Cortana (Microsoft), and Alexa (Amazon). A specialized chatbot named Vik provides breast cancer patients with information about treatments, epidemiology, quality of life improvement strategies, side effects, and practical details such as patients' rights and reimbursement.

Breast Cancer

According to the WHO report in 2022, breast cancer ranked second after lung cancer, accounting for 11.6% of all new cancer cases. The usefulness of chatbots for breast cancer patients has been investigated in two studies by Greer S et al. and Piau A et al. They demonstrated that chatbots could reduce anxiety and improve medication adherence in breast cancer patients, regardless of age.

Sato A et al. used a chatbot system developed

by IBM Corp and integrated it into LINE. They designed conversations, questions, and pedigrees related to the family history of Hereditary Breast and Ovarian Cancer (HBOC). They concluded that the chatbot could be a suitable substitute for genetic counseling, making this step easier and allowing genetic counselors to navigate more complex processes more efficiently.

Nearly 40 million mammographic exams are conducted annually in the United States, primarily through screening programs designed for early breast cancer detection. This practice is closely linked to improved survival rates. However, interpreting this vast amount of data for cancer indications depends on one or more skilled readers, a process that is both time-consuming and prone to human error. To improve healthcare quality, Computer-Aided Detection and Diagnosis (CAD) systems have been developed and are increasingly used as secondary readers. In the United States, adoption rates have reached up to 70% in hospital settings and 85% in private institutions. Unlike human readers, computers maintain consistent performance, are not affected by lapses in attention, and can undergo extensive training on a volume of samples far beyond what any individual radiologist could encounter in their lifetime.

Until recently, the effectiveness of CAD systems and other pattern recognition applications heavily relied on radiologists' input in the feature design

process. Radiologists incorporated characteristics such as lesion contrast, spiculation patterns, and border sharpness, particularly in mammography. However, these feature transformations introduced a bias toward human perception in task execution. With the rise of Artificial Intelligence (AI) as a scientific discipline, there has been a shift from rule-based, problem-specific approaches to more generic, problem-agnostic methods based on learning, with deep learning representing the latest evolution. By directly extracting information from training samples instead of relying solely on domain experts, deep learning enables optimal use of the ever-expanding data volumes while reducing human bias. This approach has achieved remarkable success in numerous pattern recognition tasks, with some systems now matching or even surpassing human performance.

The term "deep" refers to the layered non-linearities within learning systems, allowing models to represent complex functions with fewer parameters and facilitating more efficient learning. While these models are not new and have been under development since the late seventies, interest in them was reignited in 2006 when research demonstrated the feasibility of training deep networks in a greedy, layer-wise manner. Today, fully supervised Convolutional Neural Networks (CNNs) dominate performance benchmarks. Their improved performance

compared to previous decades is largely due to more efficient training methods, advancements in hardware such as many-core computing, and, most importantly, the availability of large volumes of annotated training data.

Research on CAD for mammography has been ongoing since the early nineties, but progress has largely stagnated over the past decade. Many methods are developed using small datasets, which are not always shared, making it difficult to compare algorithms effectively. In mammography, breast cancer primarily presents as malignant soft tissue masses and microcalcifications, and separate systems have been developed to detect each manifestation. Microcalcifications, which are often small and easily overlooked, have been effectively addressed by CAD systems, reducing oversight with acceptable rates of false positives. However, the effectiveness of CAD for detecting masses is less clear, as research suggests that human errors often stem more from misinterpretation than from simple oversight. Some studies show no improvement in sensitivity or specificity when using CAD for masses, and in some cases, a decrease in specificity has been observed without a corresponding improvement in detection rates or the characterization of invasive cancers.

The World Health Organization emphasizes that improving adherence to treatments would significantly impact global health, potentially

surpassing the benefits of developing new medications. In oncology, patient noncompliance is often due to the adverse effects of anticancer drugs and the characteristics of emerging therapies, such as oral chemotherapies, which accounted for 50% of cancer treatments in 2020. These therapies shift the responsibility of treatment administration from healthcare providers to patients. Additionally, the number of cancer patients is rapidly increasing, with 32.6 million cases and an annual growth of 17 million. With 50% of patients surviving beyond five years, cancer is increasingly being managed as a chronic condition. As a result, the majority of cancer patients receive treatment at home and must independently manage their regimens.

Breast cancer, with a mortality rate of approximately 11%, is the second leading cause of cancer-related deaths after liver cancer. The typical treatment for breast cancer involves comprehensive multimodal strategies. Chemotherapy, a standard therapy, has shown clear benefits in improving survival rates and reducing cancer-related symptoms. However, chemotherapy is known for causing significant organ toxicity, resulting in various immediate, short-term, and long-term side effects for patients. The assessment of this toxicity's severity, frequency, duration, and associated distress should include both objective and subjective factors. Furthermore, the adverse effects of

chemotherapy can profoundly impact patients' physical and mental well-being, potentially leading to poor adherence, decreased quality of life, increased morbidity, and even mortality.

The widespread occurrence of physical and mental distress among patients, along with the demand for better self-care guidance, suggests that current pre-chemotherapy preparation is insufficient. Numerous studies have indicated that patients often have significant unmet needs for self-care information. However, many of these studies have only focused on changes in patient education related to specific side effects, such as oral mucositis or fatigue.

Empowerment education, an innovative and effective health education approach, has shown promise in enhancing individuals' confidence to modify unhealthy behaviors. This approach emphasizes self-health management and aims to empower patients to prioritize their health and actively manage their disease by motivating them internally.

Interventions that use technology for cancer management have gained increasing popularity. In recent years, mobile technology and internet-based patient education have received significant attention. As a technological tool, chatbots can potentially enhance the efficiency and timeliness of information dissemination. These automated text-messaging systems can provide information to patients in response to their inquiries. Unlike

traditional paper-based discharge instructions, chatbots enable healthcare providers to promptly convey specific details upon request. Studies have reported positive outcomes for support chatbots for breast cancer patients, with an overall satisfaction rate of 93.95%. Chatbots can function as virtual assistants, performing roles such as symptom checkers, medication reminders, and personal data collectors.

Healthcare professionals often find chatbots convenient for simple, automated logistical tasks, but they have concerns about their ability to handle more complex functions. The limitations of chatbots arise from their underlying algorithms, data-sharing capabilities, scalability, and the level of security and privacy they provide to users. Nevertheless, chatbots are believed to provide information and guidance to multiple individuals simultaneously, creating a sense of personalized engagement.

Some studies have shown that chatbots significantly improve medication adherence among female breast cancer patients by providing them with continuous access to comprehensive information about proper medication usage, potential side effects, and strategies for managing them. In contrast, women in standard care groups did not receive remote support or follow-up phone calls from healthcare providers between their chemotherapy appointments. Consequently, these women lacked reliable sources of information

when dealing with chemotherapy side effects at home. They either relied heavily on the general information provided by nurses on the day of chemotherapy or sought information from alternative sources, such as the internet, fellow patients, family, or friends. While the study did not include qualitative data to validate the use of these strategies, both approaches may prove ineffective or counterproductive. Healthcare professionals have expressed concerns regarding the accuracy and reliability of information obtained from the internet or non-professional sources, cautioning about the potential negative repercussions of misinformation.

Patients' ability to remember information is a known issue. Studies indicate that patients forget 50-80% of the health information provided by healthcare professionals once they leave, and about half of what they remember is incorrect. Therefore, it is likely that these women did not fully benefit from the information given by nurses on the day of their chemotherapy treatment.

Access to adequate, trustworthy, and valuable information has been shown to increase feelings of empowerment and responsibility among women living with breast cancer, aiding them in managing their symptoms and improving their health. Some research has demonstrated that being well-informed about self-care behaviors can decrease chemotherapy-related side effects and associated distress.

In 2019, a study found that individuals who interacted with a chatbot experienced a decrease in anxiety following cancer treatment compared to the control group. Conversely, the study also revealed an increase in psychological distress among women who received nurse-led education and a rise in physical symptoms of distress among those who received routine care, compared to their initial state. This finding may indicate that these women struggled to manage the side effects of chemotherapy while at home. It is plausible that these individuals required professional and psychological support and sought to establish a connection with their nurses to receive dependable information between chemotherapy sessions to better manage their symptoms. A previous study suggested that equipping women living with breast cancer with knowledge and strategies to handle their symptoms effectively could alleviate symptom distress.

There has been ongoing discussion about chatbots' ability to provide basic information and answer simple patient questions effectively. However, they cannot handle complex issues or understand the nuances of human emotions, indicating that they are unlikely to replace human interaction. This means that chatbots are not a replacement for nurses but can assist nurses in helping and educating women who have undergone chemotherapy for specific types of cancer, such as breast cancer, in managing the related side effects.

Telemedicine uses telecommunications technology to deliver healthcare to underserved populations. Originally developed to aid astronauts in space, telemedicine quickly transitioned to improving access to care for people on Earth. Since its inception in the 1970s, telemedicine technology has advanced significantly, becoming more portable, user-friendly, cost-effective, and of higher quality. From the National Aeronautics and Space Administration's pioneering STARPAHC Project to the diverse array of telemedicine services available in the United States today, telemedicine has been thoroughly tested in various clinical settings. Most research indicates that it is as effective as in-person care, with high levels of satisfaction reported by patients and healthcare professionals. In some cases, telemedicine has even produced better outcomes than traditional in-person care. These findings have fueled ongoing interest in improving healthcare delivery by integrating teleconsultations with traditional in-person clinical care.

The Arizona Telemedicine Program and others have started offering telegenetic services to urban and rural communities, based on knowledge from using telegenetics with children. The extensive research on phone consultations for genetic care justified the decision to expand to these populations. The telemedicine approach has successfully identified genetic carriers and

achieved high levels of patient satisfaction. Teleoncology services are exploring the remote monitoring of chemotherapy administration. Challenges include conducting physical examinations, which can be done virtually except for palpation. Training in conducting virtual physical examinations is crucial for overall success. Collaborating with the referring clinician regarding physical examination findings can help address the inability to palpate. Some programs rely entirely on local physical examinations. Portable, home-based, and mobile technologies can be used for home health follow-ups, which may involve wound care, symptom management, and palliative care.

Access to cancer clinical trials can be challenging for patients in rural areas. Even if patients don't have to travel long distances for cancer treatment, the extra time commitment involved in enrolling in clinical trials can discourage participation. Telemedicine could help improve access to cancer clinical trials by assisting with eligibility assessments, consent, participation, and follow-up, including symptom assessment and management.

Breast Cancer Management

Early-Stage Breast Cancer

AI chatbots support patients with early-stage breast cancer by providing information and

educational resources. For instance, the "Ask Rosa" chatbot assists patients with questions about BRCA genetic testing, helping them understand their risk and management options. Additionally, telemedicine platforms enable remote consultations and follow-ups, ensuring continuous support without frequent hospital visits.

Locally Advanced Breast Cancer

In cases of locally advanced breast cancer, AI chatbots can offer personalized treatment recommendations based on large datasets and clinical guidelines. These chatbots analyze patient data to suggest optimal chemotherapy regimens and predict potential side effects. The integration of AI in multidisciplinary oncology conferences has shown promise in improving decision-making for surgical planning and radiotherapy.

Metastatic Breast Cancer

For metastatic breast cancer patients, continuous monitoring and symptom management are crucial. AI chatbots facilitate this by regularly checking in with patients and alerting healthcare providers about any concerning symptoms. This proactive approach helps manage complications and improve the quality of life. Telemedicine services provide ongoing support and consultation, which is particularly beneficial for managing complex cases remotely.

Early Detection and Diagnosis

AI technologies, especially machine learning (ML) and natural language processing (NLP), are revolutionizing the early detection and diagnosis of breast cancer. Advanced algorithms, including convolutional neural networks (CNNs) and support vector machines (SVMs), analyze mammograms, ultrasounds, MRIs, and histopathological images to identify malignant changes with high sensitivity and specificity. These technologies can detect microcalcifications and architectural distortions that might be overlooked by human radiologists, significantly enhancing early diagnosis rates.

AI systems, such as those developed by Google Health, have demonstrated capabilities in reducing false positives and negatives in mammography, leading to earlier intervention and improved survival rates. Additionally, AI tools that integrate clinical and genetic data enhance the precision of risk stratification models, allowing for personalized screening programs tailored to individual risk profiles.

Personalized Treatment

The role of AI in personalized treatment for breast cancer is groundbreaking. By integrating genomic data, clinical histories, and treatment outcomes, AI algorithms can formulate individualized therapeutic strategies. AI-driven

platforms analyze gene expression profiles (such as those from Oncotype DX and MammaPrint tests) to predict responses to chemotherapy, hormonal therapies, and targeted treatments, thus aiding oncologists in devising the most effective treatment plans.

AI also significantly optimizes radiation therapy. Techniques like intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) are enhanced by AI algorithms that precisely contour tumors and critical structures, minimizing radiation exposure to healthy tissues. In drug discovery, AI assists in identifying novel drug targets and predicting the efficacy and safety of new compounds, accelerating the development of innovative treatments.

Telemedicine and Patient Monitoring

Telemedicine, supported by AI chatbots, is transforming patient monitoring and follow-up care in breast cancer management. AI chatbots provide real-time support, answer patient inquiries, and guide symptom management and treatment adherence through advanced NLP. These chatbots deliver accurate information comparable to healthcare professionals, improving patient satisfaction and engagement. Moreover, telemedicine facilitates virtual multidisciplinary team (MDT) meetings, enabling seamless collaboration among oncologists,

radiologists, surgeons, and other specialists. This approach ensures comprehensive patient care, expedites decision-making, and reduces the time from diagnosis to treatment, ultimately improving clinical outcomes.

AI Chatbots in Breast Cancer

The Rosa chatbot was created to facilitate human-like digital conversations on the subject of hereditary breast and ovarian cancer. The testing and development processes of Rosa have been detailed in earlier sections. By employing natural language processing and machine learning, the Rosa chatbot was developed on a commercially accessible platform that supports the Norwegian language. Its database comprises predefined answers about hereditary breast and ovarian cancer, prepared by geneticists and genetic counselors from all Norwegian health regions. The chatbot does not generate answers independently, which ensures the reliability of the information it provides—an especially important aspect in healthcare. If a question is asked that does not match any of the predefined answers, the chatbot presents a fallback response, indicating that the question is not understood.

To facilitate interactions between the natural language processor and patients, a web application programming interface and a mobile app (named Rosa) were developed. The mobile app serves as an interface for patient interaction. The level of

artificial intelligence within Rosa is limited to interpreting patients' questions and selecting the appropriate answers. Patients can download the Rosa app onto their smartphones. Some of the features within Rosa include "read more" buttons, chat functions, links to associated websites, general information about cancers related to BRCA mutations, and educational videos. This application aims to support patients and their relatives throughout the genetic counseling process and potentially during genetic testing for diagnosing hereditary breast and ovarian cancers. However, Rosa does not include personalized communication features. For instance, it cannot remind users about upcoming follow-up appointments or present genetic test results. Based on extensive user and usability testing, Rosa only provides quality-assured information tailored to the specific needs of this patient group. A study in Norway invited 175 patients for genetic counseling, either due to a relevant cancer history in their family that warranted BRCA1/2 genetic testing or due to the presence of a known BRCA1/2 mutation in their family. Participants were encouraged to download the app and use it as they saw fit.

The Characteristics of Participants

Among the interviewed subjects (n=16), 14 were female and 2 were male, with ages ranging from

20 to 55 years. During the interviews, 8 of the 16 participants reported knowing of a close relative carrying a BRCA1/2 mutation, resulting in a 25%-50% risk of them carrying the familial mutation. Three of these eight participants had been informed that they had inherited the mutation. Two were unaware of their genetic status, and three had received negative genetic test results. The remaining 8 participants had no known familial mutation and eventually received negative test results. The interviews lasted between 20 and 40 minutes. Notably, only one of the 16 participants mentioned downloading the Rosa app before visiting the genetic counselor. Most participants (13 out of 16) stated during the interviews that they found the Rosa app to be a helpful tool before their first counseling session, as it prepared them for the next steps. They evaluated the app based on their beliefs about its value throughout the genetic process and as a tool beyond the period in which they had personally used it.

Accessibility

Accessibility to the Rosa app emerged as a key finding early in the analysis phase. Several subjects (13 out of 16) highlighted its 24/7 availability. The fact that all data concerning genetic tests were collected in the app made it easier for them to get answers to their questions. Since some subjects did not know what questions to ask, the

app includes "read more" recommendations after providing each answer. All participants (16 out of 16) found this function to be very helpful and smart. Instead of having to think about which relevant questions to ask on topics they were previously less informed about, users could continue learning through the guidance provided by the chatbot.

A Supplementary Tool

All participants (16 out of 16) expressed a preference for accessing both genetic counseling sessions and the chatbot. Most (12 out of 16) stated that the Rosa app is best suited as a supplement to genetic counseling, rather than serving as a replacement. They emphasized that while the app cannot replace a conversation, it is more suited to replace internet searches. It served as a useful tool throughout the genetic counseling process. Participants appreciated having the Rosa app to revisit and read the information they had received during counseling sessions as often as they needed. When asked if the app could replace genetic counseling, most (9 out of 16) emphasized their preference for conversations through face-to-face, phone, or video means, in addition to using the app. They found that combining genetic counseling with access to the Rosa app provided comfort, making the situation less intimidating. Some participants expressed a preference for having access to the app before attending genetic

counseling sessions, so they could better prepare themselves. One participant, who downloaded the app only a few days before her pre-test counseling session, affirmed that the information presented by the app did not cause worry or anxiety. On the contrary, she felt calm as she had acquired some basic information and had a general understanding of what to expect in the session. The information obtained through the app eased the difficulty of the situation for her. Other participants with similar views wished they had more information on hereditary cancer before attending the counseling session, as this would help them prepare more tailored or specific questions based on their personal circumstances. Some subjects (8 out of 16) referred to the absence of a human touch in the chatbot. They pointed out that the app did not acknowledge their feelings or ask how they felt. As a result, they were unable to ask follow-up questions, such as, "I don't quite understand. Could you explain it in a different way?" Several participants (7 out of 16) also mentioned missing smiles and eye contact, which they felt hindered communication with the app.

Trustworthy

The participants trusted the Rosa app because it was developed by healthcare personnel. A large number of participants (10 out of 16) reported that using the Rosa app in conjunction with genetic counseling made them feel more

comfortable. When one participant was asked about the credibility of the information, she noted that the app seemed to be created by a professional. She also emphasized that the information was explained in simple terms, despite the use of some complex words. Some subjects (8 out of 16) mentioned that the chatbot's language felt like that of a physician, making the content seem trustworthy, as if they were speaking to a doctor or nurse.

All participants (16 out of 16) expressed a positive attitude toward the fact that the app was developed by healthcare personnel and provided through healthcare services. None of the participants (0 out of 16) doubted the chatbot's content or felt the need to double-check the information provided by the app. Several participants (6 out of 16) emphasized that the agreement between the information from their genetic counselor and the Rosa app made the app's content seem more trustworthy, highlighting the importance of receiving information from multiple sources.

Half of the participants (8 out of 16) stated that after reading the information provided by the Rosa app, they felt more confident. They specifically highlighted an enhanced ability to make the right choices for themselves. When asked about the necessary features of a tool like this app, one participant stated that it must help users feel safe and informed in deciding whether

to undergo genetic testing and understand how such a decision could impact their lives. Seven out of 16 participants reported feeling unburdened, as if they had a tool capable of helping them cope with the potential genetic risks. Most (11 out of 16) noted the value of having access to the app in the early phases of the process, particularly before undergoing genetic testing, while also finding it to be an invaluable resource later on. They valued the fact that the app could be used to answer questions from family members, ensuring the truthfulness of the information they shared.

When participants (16 out of 16) were asked about their reactions to reading about potentially sensitive topics, such as hereditary cancer, through a chatbot, none (0 out of 16) reported feeling more anxious, nervous, or stressed. This finding addressed one of the main concerns prior to the investigation. On the contrary, several individuals (12 out of 16) stated that the facts presented were not of a frightening nature.

Lung Cancer

Cancer is the second leading cause of death worldwide, following cardiovascular disorders. In 2024, it is estimated that more than 2 million new cancer cases and 611,720 cancer-related deaths will occur in the United States. Lung cancer is the most prevalent malignancy and the leading cause of cancer-related deaths among adults globally. According to the WHO report in 2022, lung cancer

accounts for 12.4% of all new cases and 18.7% of all cancer deaths.

Cancer patients may benefit from AI-driven software or chatbots due to technological advancements. A chatbot is a software application designed for computers or smartphones that interacts with people through voice or text-based conversations.

Kataoka Y et al. developed a chatbot to assist lung cancer patients by answering their questions. They integrated the chatbot into LINE, a social media platform. The chatbot interacts with patients by providing answers based on frequently asked questions gathered from similar patients. In their study, the mean satisfaction score was 2.7 (out of 5). They suggested that the chatbot could reduce the workload and burnout of medical staff while enhancing their knowledge in addressing patients' inquiries. However, in a study by David E. Gyorki et al., a chatbot did not show good performance in the treatment of lung malignancy, as well as breast and prostate cancers.

In their evaluation of the role of large language model (LLM) chatbots in establishing treatment suggestions consistent with the National Comprehensive Cancer Network (NCCN) guidelines, they found non-concordant responses in at least one-third of the suggestions. They concluded that LLM chatbots should no longer be used for treatment recommendations. However, one advantage of chatbots is their virtual nature.

According to Lucas et al., disclosing private information to a chatbot is often easier than to a real person, partly because chatbots, unlike humans, do not make judgments.

Chaix B et al. tested a chatbot named Vik, designed by Wefight Inc, in breast cancer care. Patients shared conversations with Vik easily, especially on intimate topics like hair loss and sexual issues. Vik was helpful in treatment adherence by reminding patients to take medications, explaining how to use them, teaching about side effects, and providing ways to avoid them. Surprisingly, patients also developed an emotional bond with the chatbot and appreciated its help by the end of use.

The authors believe that having conversations with a chatbot like Vik could enhance the accuracy of patient recall before an in-person visit.

Some studies have focused on telemedicine systems addressing various cancers, including lung cancer. Lung cancer is one of the types discussed in these papers. The studies detail the development of interactions among different groups within the healthcare system to provide medical care to lung cancer patients. On one side of these interactions were patients and patient-family caregiver pairs, while on the other side were healthcare professionals, including treating physicians, clinical pharmacists, certified yoga therapists, integrative oncology physicians, and medical oncologists.

Telemedicine employs a range of technologies such as cloud computing, mobile devices, communication tools, and the Internet of Things (IoT). The research studies analyzed utilized these technologies to provide real-time counseling through telemedicine systems. Physicians were able to offer medication advice to patients via messaging through mobile and cloud-based applications. The application connected the private cloud-based hospital information system to the public cloud-based hospital information system via a web services Internet tool. Prescriptions were validated using an automated drug rationale review system integrated into the cloud-based hospital information system. Patient-family caregiver pairs and certified yoga therapists used FaceTime or Zoom for videoconferencing activities via laptops and phones. Oncology physicians utilized Zoom as a communication platform for video consultations and managed all appointments using the EPIC electronic health record system. Medical oncologists used social media and telematic consultations via phone or email to screen their patients, replacing face-to-face follow-up visits with email or phone calls and conducting telematic evaluations of computed tomography (CT) scan images. Consequently, new technologies like mobile and cloud computing have the potential to enhance patient-physician communications.

Clinic staff are increasingly focusing on patients'

quality of life (QOL) in addition to their lifespan as cancer treatment advances. It is acknowledged that individuals with lung cancer experience more symptoms compared to those with other forms of cancer. Lung cancer patients recovering from surgery spend a significant amount of time managing the aftermath and experiencing decreased lung function. Patients not suitable for surgery might face considerable discomfort and distress during chemotherapy or radiotherapy. Providing immediate and ongoing feedback from doctors about their suffering could offer substantial comfort and assistance. In response, electronic health web systems and applications have been developed to facilitate convenient communication between clinic staff and patients, potentially enhancing patients' quality of life. However, a randomized controlled trial has indicated that combining symptom telemonitoring with active patient feedback did not show superiority over the relatively passive approach of symptom telemonitoring alone in maintaining the well-being of lung cancer patients.

The use of chatbots and telemedicine presents a distinct advantage in improving the quality of life (QOL) and psychological well-being of patients with lung cancer, leading to reduced levels of reported anxiety and depression. Telemedicine is an effective intervention for the holistic management of lung cancer patients' well-being.

In general, artificial intelligence (AI) holds the potential to significantly transform cancer treatment and align it more closely with the principles of precision oncology. As genomics becomes more integrated into healthcare delivery and health data becomes increasingly prevalent, the impact of AI is expected to be substantial. Digitized health data will allow AI to play a crucial role in developing, validating, and implementing decision-support tools to advance precision oncology. This review highlights several promising AI applications, including cancer detection, prognosis, and treatment management. While large language models can greatly support physicians in their clinical work, they can never fully replace them. Essential prerequisites for the widespread adoption of AI in clinical settings include comprehensive data for model development and the clinical validation of AI-generated insights. Ultimately, clinical validation of AI is necessary before it can be integrated into routine patient care.

Lung Cancer Management

Non-Small Cell Lung Cancer (NSCLC)

AI chatbots significantly impact the management of NSCLC by aiding in the early detection and diagnosis of lung nodules. AI algorithms analyze imaging data to identify suspicious nodules and

provide detailed reports to radiologists, thereby enhancing diagnostic accuracy. Additionally, these chatbots can predict responses to different treatment modalities, assisting in personalized treatment planning.

Small Cell Lung Cancer (SCLC)

For SCLC, which is typically more aggressive, AI chatbots and telemedicine platforms facilitate timely interventions and continuous monitoring. These technologies help manage the rapid progression of symptoms and side effects by providing real-time support and adjusting treatment plans as needed. Telemedicine ensures that patients have immediate access to their healthcare providers, which is crucial for managing acute symptoms and complications.

Post-Treatment and Survivorship Care

In the post-treatment phase, AI chatbots assist in monitoring patients' recovery and managing long-term side effects. A smartphone chatbot application developed for older cancer patients receiving chemotherapy at home demonstrated that AI could effectively monitor health status and prompt timely interventions. Telemedicine platforms provide continuous support and follow-up care, ensuring that patients remain engaged with their healthcare providers and adhere to their post-treatment plans.

Early Detection and Diagnosis

Lung cancer detection and diagnosis have significantly benefited from AI technologies. AI algorithms, particularly those based on deep learning, analyze CT scans, X-rays, and biopsy samples to identify lung nodules and differentiate between benign and malignant lesions with high accuracy. These systems excel in detecting early-stage lung cancers, which are often asymptomatic and missed by traditional methods, thereby improving prognosis and survival rates.

AI also enhances predictive risk models by integrating patient demographics, smoking history, genetic predispositions, and imaging data. Such comprehensive models facilitate personalized screening strategies and early interventions, which are crucial for lung cancer patients who often present with advanced disease at diagnosis.

Personalized Treatment

AI-driven personalized treatment strategies are transforming lung cancer management. These algorithms analyze extensive datasets, including genomic information, clinical histories, and treatment outcomes, to recommend individualized therapeutic regimens. AI can predict patient responses to various therapies, such as chemotherapy, targeted therapies (e.g., EGFR inhibitors), and immunotherapies (e.g.,

PD-1/PD-L1 inhibitors), helping oncologists select the most effective treatment plans.

Additionally, AI supports radiotherapy by optimizing treatment plans through techniques like stereotactic body radiotherapy (SBRT) and adaptive radiation therapy (ART). These methods allow for precise targeting of tumors, minimizing damage to adjacent healthy tissues and reducing treatment-related side effects. AI tools also monitor treatment responses in real-time, enabling dynamic adjustments to therapy and improving patient outcomes.

Telemedicine and Patient Monitoring

Telemedicine, enhanced by AI chatbots, is a cornerstone in managing lung cancer, particularly in remote and underserved areas. AI chatbots provide continuous monitoring and support, addressing patient queries, managing symptoms, and ensuring treatment adherence through sophisticated NLP and dialogue management systems. These chatbots significantly improve quality of life (QoL) by reducing anxiety and depression among lung cancer patients.

Telemedicine platforms facilitate virtual MDT meetings, allowing specialists to discuss complex cases and develop comprehensive treatment plans. This model enhances access to expert care, reduces patient travel burdens, and accelerates the initiation of treatment, which is critical for

lung cancer patients who require prompt and coordinated care.

AI and Imaging

Mammography

Mammography is considered the gold standard and one of the most efficient imaging techniques for identifying abnormalities in the breasts. However, digital mammography has limitations, including a false-positive screening rate, which increases recalls for radiologists, elevates workloads, incurs unnecessary costs, and introduces variations in radiologists' performance. These variations can result in false-negative outcomes, leading to missed diagnoses in up to 30% of breast cancer patients in low-prevalence conditions. To address these disadvantages, computer-aided detection (CAD) systems were introduced.

Traditional CAD systems, however, had lower specificity, increased recall rates, and did not significantly enhance breast cancer detection despite being designed to improve radiologists' performance in reading mammograms. In recent years, advancements in AI as a branch of computer science have made it superior to traditional CAD systems. AI now has the capability to identify missed lesions that are invisible to the human eye, thereby reducing misdiagnoses.

Today, many AI applications are developed to

aid in the triage, classification, risk assessment, and density assessment of breast cancer using mammography. The FDA-approved applications include Saige-Q for breast cancer triage and Transpara for the classification and detection of breast cancer.

Sonography

Ultrasound (US) serves as a primary screening tool for breast cancer, especially in young women, patients who cannot undergo MRI, and during pregnancy. Additionally, US is used as image guidance for breast biopsies and as a supplemental screening method for dense breasts that have already undergone mammography. Due to its higher sensitivity but lower specificity compared to mammography, AI applications for ultrasound are primarily designed to differentiate between benign and malignant breast tumors. Two FDA-approved applications, Koios DS and S-Detect, are used for lesion classification of breast cancer through ultrasound.

AI applications assist radiologists in making accurate diagnoses, as ultrasound is an operator-dependent modality. These AI tools help radiologists reach the best decisions by providing precise diagnostic information.

MRI

Magnetic Resonance Imaging (MRI) is a non-invasive imaging modality with high

sensitivity for high-risk screening, diagnosis, and preoperative staging of breast cancer. However, MRI has disadvantages, such as being time-consuming due to the need for numerous imaging sequences, high cost, limited availability, variable specificity, and false-positive findings, which can lead to unnecessary invasive biopsies. AI-based algorithms, particularly those implementing deep learning applications, can significantly reduce the false-positive rate in MRI.

MRI is likely the modality that provides the most data for AI applications. By extracting large datasets, AI can be utilized for the detection of suspicious lesions, classification (benign versus malignant), and segmentation of breast cancer. This integration of AI into MRI imaging aids in more accurate and efficient breast cancer diagnosis and management.

Ethical and Practical Considerations

The integration of AI chatbots and telemedicine into cancer care presents several ethical and practical considerations that must be addressed to ensure their successful adoption and implementation.

Data Privacy and Security

The use of AI and telemedicine involves the collection and processing of vast amounts of personal health data. Ensuring the privacy and

security of this data is paramount. Robust data protection measures must be in place to prevent unauthorized access and breaches. Compliance with regulations such as GDPR and HIPAA is essential to maintain patient trust and confidentiality.

Accuracy and Reliability

AI chatbots must provide accurate and reliable information to avoid misinformation and potential harm to patients. Continuous monitoring and updating of AI algorithms are necessary to ensure they reflect the latest medical knowledge and guidelines. Regular validation and testing of these systems help maintain their accuracy.

Human Oversight

While AI chatbots can significantly aid in cancer care, they should not replace human judgment. Physicians should oversee AI-driven recommendations and intervene when necessary. This collaborative approach ensures that AI serves as a support tool rather than a replacement for human expertise.

Access and Equity

Telemedicine and AI technologies must be accessible to all patients, regardless of their socioeconomic status or geographic location. Efforts should be made to bridge the digital

divide and ensure that underserved populations can benefit from these advancements. Policies and programs aimed at improving digital literacy and access to technology are crucial.

Ethical Use of AI

The deployment of AI in healthcare must adhere to ethical principles, including transparency, accountability, and fairness. AI systems should be designed to avoid biases and ensure equitable treatment for all patients. Ethical guidelines and frameworks should guide the development and implementation of AI technologies in cancer care.

AI Chatbots in the Management of Breast and Lung Cancers

Role and Functions

Symptom Assessment and Triage: AI chatbots play a crucial role in the early detection and differentiation of cancer-related symptoms from other conditions. They can assess symptoms specific to breast and lung cancers and provide initial triage recommendations, improving early diagnosis and treatment outcomes.

Patient Education and Support: Chatbots offer tailored information on treatment options, side effects, and lifestyle adjustments. For example, patients with breast cancer have benefited from chatbots providing educational support, leading to a better understanding and management of

their condition.

Monitoring and Follow-Up Care: AI chatbots regularly check in with patients to track symptoms, medication adherence, and overall well-being. This ongoing interaction helps manage ongoing care and follow-up efficiently, ensuring timely interventions.

Benefits

Accessibility and Convenience: AI chatbots provide 24/7 availability and support, which is crucial for patients with limited access to healthcare facilities, particularly those in rural or underserved areas.

Personalized Interaction: These chatbots customize responses and recommendations based on individual patient data and history, thereby improving patient satisfaction and outcomes.

Data Collection and Tracking: AI chatbots collect valuable patient data that can inform clinical decisions and enhance care strategies. This data-driven approach leads to better management strategies.

Challenges and Limitations

Accuracy and Reliability: Ensuring that AI provides accurate and actionable advice is a significant challenge. Current limitations in AI technology can sometimes result in incorrect or incomplete recommendations.

Patient Trust and Acceptance: Building and

maintaining trust in AI-driven healthcare interactions is essential. Strategies to improve patient engagement and acceptance are crucial for the successful deployment of chatbots.

Ethical and Privacy Concerns: Ensuring data security and patient privacy is paramount. Ethical considerations in deploying AI chatbots must be addressed to maintain patient trust and compliance.

Telemedicine in the Management of Breast and Lung Cancers

Implementation Strategies

Remote Consultations and Follow-Ups: Telemedicine facilitates virtual visits for diagnosis, treatment planning, and ongoing care. Successful models have demonstrated significant improvements in care delivery for breast and lung cancer patients.

Tele-radiology and Tele-pathology: Remote analysis and interpretation of imaging and pathology reports enhance diagnostic accuracy and efficiency, enabling timely interventions.

Virtual Tumor Boards and Multidisciplinary Meetings: Telemedicine supports coordinated care among oncologists, radiologists, surgeons, and other specialists through virtual tumor boards, improving collaborative care and treatment outcomes.

Advantages

Improved Access to Care: Telemedicine enhances access to specialist care for patients in remote or underserved areas, significantly improving healthcare delivery.

Cost Reduction: By reducing travel expenses, time off work, and other associated costs for patients, telemedicine proves to be an economically viable option for cancer care.

Enhanced Continuity of Care: Telemedicine ensures consistent monitoring and follow-up, particularly during treatment and survivorship phases, guaranteeing uninterrupted care.

Challenges and Barriers

Technological Limitations: Issues with internet connectivity, access to necessary devices, and user proficiency can hinder the effectiveness of telemedicine services.

Regulatory and Reimbursement Issues: Navigating varying regulations and securing payment for telemedicine services are significant barriers that need to be addressed for wider adoption.

Quality of Care: Maintaining high standards of care in a virtual environment is crucial. Ensuring that remote care matches the quality of in-person visits is essential for patient satisfaction.

Case Studies and Real-

World Applications

AI Chatbots in Breast Cancer Management:

Specific examples and outcomes of AI chatbot usage for breast cancer patients show improvements in patient engagement and outcomes.

AI Chatbots in Lung Cancer Management: Case studies demonstrate the effectiveness of AI chatbots in lung cancer care, including symptom tracking, patient education, and support.

Telemedicine Programs in Oncology: Examples of telemedicine programs implemented during the COVID-19 pandemic highlight their impact on patient outcomes and care continuity.

Patient Outcomes and Feedback: Analyses of patient satisfaction and clinical outcomes from implemented technologies reveal positive feedback from breast and lung cancer patients.

Comparative Analysis

Traditional Cancer Care Models vs. AI Chatbot and Telemedicine-Enhanced Models: Comparing patient outcomes, satisfaction, and efficiency, case studies highlight the benefits and drawbacks of each approach.

Cost-Effectiveness: Economic analyses of integrating AI chatbots and telemedicine in breast and lung cancer care demonstrate cost savings and improved resource utilization.

Impact on Quality of Life and Survival Rates: Studies show improvements in patient quality of

life and survival rates, with long-term outcomes favoring the use of these technologies.

Future Directions and Innovations

Emerging Trends: Advances in AI algorithms and telemedicine platforms for oncology suggest potential future technologies and their implications for cancer care.

Potential Advancements: Innovations in personalized cancer treatment plans that integrate AI and telemedicine highlight ongoing research and development.

Prospects for Comprehensive Cancer Care: The future integration of AI chatbots and telemedicine with traditional therapies could lead to holistic care models, significantly impacting patient outcomes.

Ethical and Legal Considerations

Privacy and Data Security: Ensuring robust safeguards for patient data is critical. Current best practices and future challenges must be addressed to protect patient information.

Regulatory Compliance: Adhering to evolving legal frameworks for telemedicine and AI in healthcare is essential for compliance and widespread adoption.

Ethical Implications: Addressing concerns around AI decision-making and patient consent is crucial for the ethical deployment of AI and

DR.MOHAMMAD-SOROUSHKHORSAND

telemedicine in healthcare.

AI CHATBOTS AND TELEMEDICINE IN CANCER CARE: SU...

5- AI CHATBOTS AND TELEMEDICINE IN THE MANAGEMENT OF ORAL CANCERS

Background

In recent years, advancements in artificial intelligence (AI) and telemedicine have revolutionized the healthcare industry, particularly in the management of oral cancers. These technologies offer innovative solutions for early detection, patient education, treatment monitoring, and follow-up care, thereby improving patient outcomes and enhancing accessibility to healthcare services.

AI chatbots have emerged as valuable tools in various areas of healthcare, including the management of oral cancers. These digital assistants utilize natural language processing (NLP) and machine learning algorithms to interact with patients, providing them with timely information, answering queries, and offering emotional support.

One of the primary functions of AI chatbots in oral cancer management is patient education. Patients diagnosed with oral cancer often face a steep learning curve regarding their condition, treatment options, and care requirements. AI chatbots can provide comprehensive information

about oral cancer types, symptoms, risk factors, and treatment modalities. By offering easily accessible and reliable information, chatbots help patients and their families understand the nature of the disease and make informed decisions about their care.

AI chatbots also play a crucial role in symptom management and monitoring. Oral cancer and its treatments can lead to various side effects, such as pain, difficulty swallowing, and changes in oral health. Chatbots can assist patients in tracking these symptoms and provide guidance on how to manage them. For example, a chatbot might offer tips for managing oral pain, suggest dietary adjustments, or recommend over-the-counter remedies. Additionally, by continuously collecting data on patients' symptoms and responses, chatbots can alert healthcare providers to any significant changes that may require further intervention.

Emotional support is another critical aspect where AI chatbots contribute significantly. A diagnosis of oral cancer can be distressing and overwhelming for patients and their families. AI chatbots can provide a source of comfort by offering motivational messages, connecting users with support groups, and providing access to mental health resources. This support can help alleviate some of the psychological burdens associated with cancer and improve the overall well-being of patients and their caregivers.

AI Chatbots in Oral Cancer Management

AI chatbots are increasingly being integrated into healthcare systems to assist both patients and healthcare providers. These chatbots leverage natural language processing (NLP) and machine learning algorithms to interact with patients, providing immediate responses to their queries and delivering personalized health information.

Early Detection and Screening: AI chatbots play a crucial role in the early detection of oral cancers. By engaging with patients and collecting data on symptoms, risk factors, and medical history, these chatbots analyze the information to identify potential warning signs of oral cancer. For example, a study by Esteva et al. (2020) demonstrated the effectiveness of AI in screening for skin cancer, suggesting similar applications for oral cancer screening.

Patient Education and Support: Chatbots provide patients with comprehensive information about oral cancers, including causes, symptoms, treatment options, and preventive measures. In addition, they offer emotional support and guidance, helping patients manage the anxiety and stress associated with their diagnosis. According to a study by Bibault et al. (2019), AI chatbots significantly improve patient education and engagement in oncology care.

Treatment Monitoring and Adherence: AI

chatbots assist in monitoring treatment progress and ensuring medication adherence. They can send reminders for medications, appointments, and follow-up visits, while also tracking side effects and overall health status. This continuous monitoring allows for timely interventions and necessary adjustments to treatment plans, thereby enhancing patient outcomes.

Telemedicine in Oral Cancer Management

Telemedicine involves the use of digital communication technologies to provide healthcare services remotely. It has demonstrated significant promise in managing oral cancers, particularly by improving access to care for patients in remote or underserved areas.

Teleconsultations: Telemedicine enables virtual consultations between patients and healthcare providers, reducing the need for travel and shortening waiting times. This is particularly beneficial for oral cancer patients who require frequent follow-ups and monitoring. A study by Patt et al. highlighted the effectiveness of telemedicine in oncology, noting improvements in patient satisfaction and outcomes.

Remote Diagnosis and Treatment Planning: Telemedicine facilitates remote diagnosis and treatment planning through high-resolution imaging and video conferencing. Dentists and oncologists can collaborate seamlessly to review

patient cases, discuss treatment options, and develop personalized care plans. This collaborative approach ensures that patients receive optimal care, regardless of their location.

Continuity of Care: Telemedicine promotes continuity of care for oral cancer patients by enabling regular follow-ups and monitoring. Patients can report symptoms, receive guidance, and discuss concerns with healthcare providers without needing in-person visits. This continuous care model improves adherence to treatment plans and enhances overall health outcomes.

Limitations of AI Chatbots

Despite their many benefits, AI chatbots have limitations. Currently, AI lacks the empathy, intuition, and expertise that medical professionals have developed over the years. These human qualities are crucial for effective patient care, particularly when interpreting subtle language and non-verbal signals. AI chatbots are restricted to working with predefined data and algorithms; thus, the value of their recommendations depends on the quality of the data they receive. Consequently, any subpar or biased data could lead to negative outcomes

The Crucial Role of Healthcare Workers

The crucial importance of healthcare workers cannot be overstated. A medical professional's

duties extend beyond merely diagnosing illnesses or prescribing treatments. Physicians and dentists provide comfort, reassurance, and empathy during what can be stressful and vulnerable times for patients. AI chatbots are unable to replicate or substitute the trust, rapport, and understanding that characterize the doctor-patient relationship. Additionally, while chatbots can provide general health information and manage routine tasks, their current capabilities do not extend to answering complex medical queries, such as those related to oral cancer. The complexity of these queries requires a level of medical expertise, critical thinking skills, and clinical experience that chatbots currently lack. As a result, intricate medical queries and nuanced patient interactions underscore the vital role of medical professionals in healthcare.

Oral cancer is often detected late, resulting in serious illness and death. Prompt diagnosis of lesions is essential for effective treatment, as delays in detection have been correlated with lower survival rates, more severe symptoms, and increased treatment expenses. Early detection involves diagnosing and monitoring oral conditions that could potentially develop into cancer to ensure timely and effective treatment.

Oral potentially malignant disorders (OPMDs) are oral mucosal abnormalities strongly associated with an elevated risk of developing oral cancer. OPMDs include white patches in the

mouth, excessive tissue growths, red patches, inflammatory skin conditions, scar tissue in the mouth, lesions on the palate, autoimmune disorders affecting the oral cavity, sun-damaged skin, and rare genetic disorders. Clinicians can use technology to identify and diagnose these conditions earlier, thereby improving patient care. The advancement of information technology and cutting-edge artificial intelligence (AI) offers promising prospects for enhancing oral cancer (OC) screening. AI has made remarkable progress in detecting and preventing OC at an early stage.

Analysis of Intricate Diagnostic Tests

Specialized knowledge and expertise are necessary to accurately interpret certain diagnostic tests, including MRIs, CT scans, and biopsy results. Human medical professionals possess the expertise required to examine these tests and provide precise diagnoses.

AI Chatbots in Healthcare: Assessing Their Limitations and Capabilities

The healthcare system has increasingly begun incorporating AI chatbots to streamline operations and enhance patient care. Despite their ability to perform multiple tasks, these systems have limitations and cannot replace human medical professionals in complex situations.

The Abilities of AI Chatbots

AI chatbots are capable of managing appointments, allowing patients to easily book, reschedule, or cancel appointments without human intervention. The use of chatbots to send timely reminders can help patients adhere to their medication schedules by reminding them to refill their prescriptions. Additionally, AI chatbots can assess patients' symptoms and suggest potential diagnoses accordingly. They can also sort patients based on the severity of their condition, aiding healthcare providers in prioritizing cases and efficiently allocating resources. Furthermore, AI chatbots can provide psychological support to users, offering coping strategies and resources for mental health challenges. In medical research, AI chatbots assist researchers in finding relevant literature, analyzing data, and generating summaries or reports.

Difficult Conditions That Demand the Experience of Human Medical Professionals

While AI chatbots can offer initial diagnoses using symptom analysis, rare or complex conditions typically require a thorough examination of the patient's medical history and a comprehensive evaluation by a healthcare provider.

Surgical Operations

The expertise, skill, and precision of human surgeons are indispensable for surgeries and invasive procedures, tasks that AI chatbots are incapable of performing.

Support and Empathy

Although AI chatbots can provide assistance and resources for mental health concerns, they cannot replicate the empathy and profound understanding that human therapists offer during counseling sessions.

Conclusion

The integration of AI chatbots and telemedicine into the management of oral cancers marks a significant advancement in healthcare delivery. These technologies not only enhance early detection and patient education but also improve treatment monitoring and accessibility to care. As AI and telemedicine continue to evolve, their applications in oral cancer management will likely expand, offering new possibilities for improving patient outcomes and quality of life.

6- AI CHATBOTS AND TELEMEDICINE IN THE MANAGEMENT OF HEAD AND NECK CANCERS

Background

Head and neck cancer (HNC) is a prevalent epithelial malignancy that affects various regions, including the lips, oral cavity, nasal cavity, pharynx, larynx, salivary glands, and upper trachea. The most common type of head and neck cancer is squamous cell carcinoma (HNSCC). The primary risk factors for HNC include smoking, alcohol consumption, and the presence of human papillomavirus (HPV). Treating advanced HNC remains a significant challenge. Despite modern multimodal therapeutic approaches, such as chemotherapy, radiation therapy (RT), and surgery, the prognosis remains poor, with an approximate five-year survival rate of 50%. Survivors of HNC often face long-term difficulties such as pain, swallowing issues, speech problems, trismus, and dissatisfaction with body image.

Recently, digital technologies, including artificial intelligence (AI), chatbots, telehealth, and mobile health applications, have become increasingly integrated into cancer care. These innovations assist with symptom monitoring, treatment

adherence, patient engagement with digital cancer services, and the promotion of healthy habits. Telemedicine, which utilizes communication technology and electronic information such as video, telephone, and audio, offers healthcare services to patients who have limited access to traditional care. Therefore, we assess the effectiveness of digital health tools in managing HNC patients.

HNC and its treatments often negatively impact patients' well-being and quality of life. Telemedicine interventions can improve the quality of life for individuals with HNC after treatment, proving to be both cost-effective and beneficial in managing these patients. HNC patients and their caregivers have expressed high levels of satisfaction with digital healthcare technologies (telemedicine, telemonitoring, digital therapeutics, and digital health), particularly due to their ability to detect health issues early, enhance patient management, improve quality of life, boost self-confidence, and facilitate communication. Furthermore, digital healthcare has demonstrated significant cost and time efficiency. Telehealth interventions provide an innovative method for improving access to care throughout the cancer continuum, enhancing self-management and patient knowledge, ensuring continuity of services, and enabling remote monitoring of symptoms and treatment responses in HNC patients.

Patients who utilize telehealth tend to be younger and more likely to speak English. Telerehabilitation has proven to be a practical and effective support system for HNC patients during and after their treatment. It is crucial that these interventions are tailored to each patient's individual characteristics and disease stage. The primary functions of digital tools for HNC patients include self-care, symptom tracking, preparation for and recovery from treatment, psychological support, decision-making assistance, and educational resources.

A study by Shah et al. indicated that phone calls during the early stages following HNC surgery could reduce unnecessary emergency room visits and increase patient satisfaction. This alleviates pressure on healthcare settings and contributes to overall improvements in patient care. A 2022 cross-sectional study revealed that 95% of HNC patients found telemedicine appointments satisfactory and expressed a willingness to continue using telemedicine in the future. Patients from rural and regional areas were particularly receptive to telemedicine, citing minimal disruption to their daily routine and significant savings in travel time. This approach also proved advantageous during pandemics such as COVID-19 by reducing the risk of viral transmission.

Another study evaluated telehealth use in HNC patients across six domains: information

exchange, usability, travel time and expenses, emotional comfort, rapport, and satisfaction during the SARS-CoV-2 pandemic. Overall, participants provided positive feedback in each domain, confirming that telehealth appointments adequately met their needs. Telehealth can therefore be considered a complementary option to traditional in-person visits for HNC patients.

Additionally, telemedicine has significantly improved the diagnosis of oral cancers, particularly in suburban areas. It has the potential to revolutionize the treatment, monitoring, and diagnosis of oral malignancies by enabling individuals in remote locations to access the care they need.

A systematic review of several studies demonstrated that most patients with head and neck cancer (HNC) could effectively use mobile applications for self-managing and remotely monitoring their symptoms, showing high levels of satisfaction, adherence, usability, and acceptance. The use of remote technologies for telemedicine led to an improved quality of life, linked to increased health knowledge and a greater sense of personal control. Another study found that LogPAL, an iPhone mobile health application, was accepted, feasible, and regularly used by HNC survivors for managing and tracking their symptoms post-treatment. Similarly, Li et al. reported that mobile health technology can be instrumental in helping HNC patients manage

their care and interventions after discharge. It also plays a role in alleviating both psychological and physical burdens, meeting patients' health information needs, and enhancing their quality of life.

A study conducted in 2024 assessed the responses of Google's Gemini Advanced and ChatGPT 4 in offering therapeutic recommendations for hypothetical cases of HNC. The findings showed that both provided relevant and effective treatment plans. A recent study also evaluated the reliability and accuracy of ChatGPT in responding to questions about HNC. These questions covered topics such as treatment, operative risks, follow-up, diagnosis, cancer prevention, and basic knowledge. ChatGPT provided completely correct answers to 86% of the queries, suggesting it can be a valuable source of data for both health professionals and patients.

A cross-sectional study assessed the feasibility of using AI chatbots, like ChatGPT, to provide information before HNC surgery, such as reasons for surgery, associated risks, and expected recovery times. The study compared ChatGPT's responses with those obtained from a web search, and the findings demonstrated that both sources offered similar accuracy, knowledge content, medical errors, thoroughness, and readability. Likewise, ChatGPT shows strong potential in addressing NCCN-related questions, demonstrating high accuracy and sensitivity in

follow-up care and both adjuvant and primary treatment for HNC patients.

Another investigation involving 95 HNC patients provided preliminary findings on the use of chatbots for collecting patient-reported outcomes and assisting with symptom management in patients receiving radiation therapy. Approximately 90% found the chats user-friendly, and 60% mentioned that the chats helped them manage symptoms and reduced the need to contact their care team. These findings suggest that chatbots are practical and offer valuable support to HNC patients during and after radiation therapy.

Another study illustrated the effectiveness of integrating daily electronic apps for HNC patients receiving radiotherapy. The results showed that telemonitoring led to more frequent reporting of HNC-related symptom burdens and significantly increased patient satisfaction. In 2021, a cross-sectional study revealed that lower income, lower education, and older age were associated with decreased use of technology (internet, email, computer) among HNC patients due to socioeconomic disparities. A retrospective study showed that 68% of some HNC patients were uninterested in telemedicine, primarily preferring in-person visits and examinations. Other reasons included discomfort with technology or limited access to it. Those who opted for telemedicine did so for convenience, to avoid infection (e.g.,

COVID-19), and to reduce travel distance.

Similarly, another study found that less educated, older, Black, and underinsured or uninsured HNC patients use health information technology less frequently than their peers. Addressing these disparities could potentially improve outcomes. Another cross-sectional study reported that nearly half of HNC patients were reluctant to use telemedicine, citing concerns about unreliable internet and limited access to technology. Several studies have also raised concerns regarding AI chatbots, including issues with patient confidentiality, privacy, and reliability.

ChatGPT, in particular, poses inherent limitations, including ethical concerns about accountability, authorship, transparency, the risk of spreading misinformation, and bias. Other issues with chatbots include cybersecurity risks, accuracy, technological maturity, and a lack of empathy. Wei et al. conducted a study comparing Google and ChatGPT in answering questions about HNC. Both sources were found to have similar readability difficulties. Although ChatGPT's responses were comparable in complexity to Google's, ChatGPT was considered lower in quality due to reduced accuracy and reliability. As a result, Google was found to provide better responses for HNC patients.

In conclusion, while the benefits of these technologies appear to outweigh the limitations, further research is needed to fully understand

their impact and address any remaining concerns. Artificial intelligence (AI) chatbot tools, such as the Chat Generative Pretrained Transformer (ChatGPT), are rapidly evolving in healthcare services. Their ability to process vast amounts of data and detect patterns beyond human capabilities makes them well-suited for tasks such as sending medication reminders, scheduling appointments, and providing general healthcare information to improve patient management and disease monitoring. By handling these tasks, chatbots help alleviate the burden on healthcare systems, allowing medical professionals to focus more on complex care needs.

Head and neck cancer (HNC) is the seventh most common cancer worldwide, with a 30% annual increase in incidence. HNC oncology is a complex and challenging field, involving the diagnosis and treatment of various malignancies in the head and neck region. Recently, evidence has emerged supporting AI-assisted diagnosis and treatment in HNC. Efforts have focused on developing AI machine-learning models to predict HNC cancers. Additionally, AI chatbots can enhance HNC outcomes by aiding in symptom management, screening, patient education, risk stratification, and treatment monitoring. For instance, they can provide dietary and nutritional guidance to HNC patients undergoing chemotherapy and assist patients in locating relevant clinical trials for HNC treatments. AI chatbots can also support the

education of healthcare professionals in the HNC field.

Many chatbots are capable of engaging in patient-centered communication through personalized conversations, which enhances their accessibility. In some cases, patients may feel more comfortable interacting with chatbots than with healthcare providers. Interestingly, chatbots can improve cancer care for minority and rural populations by addressing gaps in HNC care, allowing more people to receive information about screenings and genetic counseling.

Patients diagnosed with HNC often experience emotional anxiety, particularly concerning their prognosis, survival rates, and the complexities of chemotherapy and surgical procedures. Delivering timely and accurate information is crucial for managing their stress. Traditional consultations, combined with the occasional inaccessibility of healthcare personnel, may not provide enough information to alleviate anxiety. However, chatbots, with their constant availability, can promote online education and help patients better manage their stress.

AI chatbots serve as an additional source of information for patients with otolaryngological cancer, though challenges such as the "potential to misinform patients" and "suboptimal educational value" can lead to confusion. Refining AI chatbots or creating specialized versions tailored to otolaryngological cancer patients could improve

the quality of care for these individuals.

While AI chatbots significantly influence HNC patient care management, certain limitations remain:

AI Chatbots in Head and Neck Cancer Management

AI chatbots, powered by natural language processing and machine learning algorithms, have become valuable tools in patient management. These systems interact with patients through text or voice, providing information, triaging symptoms, and offering psychosocial support. In managing head and neck cancers, AI chatbots can play crucial roles in several areas:

Symptom Triage and Early Detection: AI chatbots can aid in the early detection of head and neck cancers by analyzing patient-reported symptoms and risk factors. For example, they can evaluate symptoms like persistent sore throat, hoarseness, and unexplained weight loss, which may indicate potential malignancies. By providing risk assessments and recommending further medical evaluations, AI chatbots facilitate timely diagnosis.

Patient Education and Support: Educating patients about their condition and treatment options is a vital aspect of HNC management. AI chatbots can deliver tailored educational content, answer frequently asked questions, and provide emotional support, enhancing patient

engagement and adherence to treatment plans. This continuous support is particularly valuable for managing the complex and often distressing nature of HNC.

Follow-Up and Monitoring: Post-treatment surveillance is critical in HNC to detect recurrences and manage long-term side effects. AI chatbots can assist in remote monitoring by collecting patient-reported outcomes and tracking symptoms over time. This data can be integrated into electronic health records (EHRs), enabling oncologists to make more informed decisions about follow-up care.

Telemedicine in Head and Neck Cancer Management

Telemedicine, which uses telecommunications technology to provide healthcare services remotely, has gained significant prominence, especially in the wake of the COVID-19 pandemic. Its application in head and neck cancer management covers various aspects:

Virtual Consultations: Telemedicine facilitates virtual consultations between patients and oncologists, reducing the need for frequent in-person visits. This is particularly beneficial for patients living in remote areas with limited access to specialized care. Virtual consultations support initial evaluations, treatment planning, and follow-up care, thus enhancing continuity of care.

Multidisciplinary Care Coordination: Managing HNC often requires a multidisciplinary approach involving surgeons, radiation oncologists, medical oncologists, and other specialists. Telemedicine platforms can support multidisciplinary team meetings and case discussions, ensuring comprehensive and coordinated care. This collaborative approach is essential for devising optimal treatment strategies.

Rehabilitation and Support Services: HNC patients frequently need rehabilitation services, such as speech and swallowing therapy. Telemedicine can provide these services remotely, allowing patients to receive ongoing care without the need for travel. Additionally, telehealth platforms can connect patients with support groups and counseling services, addressing the psychosocial aspects of cancer care.

Challenges and Future Directions

While the integration of AI chatbots and telemedicine in HNC management holds great promise, it also presents several challenges. Issues related to data privacy, algorithmic biases, and the digital divide must be addressed to ensure equitable access to these technologies. Moreover, the accuracy and reliability of AI chatbots in clinical decision-making require ongoing evaluation through rigorous clinical trials. Future directions include developing more sophisticated AI algorithms capable of

personalized patient interactions and integrating telemedicine with wearable devices for real-time monitoring. Additionally, policy frameworks and reimbursement models need to evolve to support the widespread adoption of these technologies.

Ethical considerations

Ensuring patient privacy and maintaining ethical standards in the use of data can pose challenges in healthcare settings involving AI.

Despite these limitations, AI chatbots hold great potential for enhancing the quality of care in HNC, though continued refinement and ethical consideration are essential for their successful integration into healthcare systems.

7- AI CHATBOTS AND TELEMEDICINE IN THE MANAGEMENT OF UROGENITAL CANCERS

Background

The advent of artificial intelligence (AI) and telemedicine represents a transformative shift in the management of urogenital cancers. These cancers, which include malignancies of the urinary system and reproductive organs, present complex diagnostic, treatment, and management challenges. Integrating AI chatbots and telemedicine into the care continuum for urogenital cancers offers promising solutions to enhance patient care, streamline treatment processes, and improve overall outcomes.

Enhancing Patient Engagement and Support Through AI Chatbots

AI chatbots have emerged as vital tools in healthcare, particularly in the management of chronic conditions and cancers. In the context of urogenital cancers, chatbots play a multifaceted role in supporting patients throughout their care

journey.

One of the primary functions of AI chatbots in urogenital cancer management is patient education. Patients diagnosed with cancers such as prostate, bladder, kidney, or testicular cancer often need comprehensive information about their condition, treatment options, and potential outcomes. AI chatbots can provide accessible and tailored educational resources, helping patients understand their diagnosis and make informed decisions about their care. For instance, chatbots can explain the differences between various treatment modalities, such as surgery, radiation therapy, and chemotherapy, and help patients understand what to expect during each phase of treatment.

AI chatbots also offer valuable support in symptom management and monitoring. Urogenital cancers and their treatments can lead to a range of symptoms, including pain, urinary issues, sexual dysfunction, and changes in bowel habits. Chatbots can assist patients in tracking these symptoms and provide advice on managing them. For example, a chatbot might offer guidance on managing urinary incontinence or suggest lifestyle modifications to alleviate discomfort. By continuously collecting and analyzing data on patient symptoms, chatbots can also alert healthcare providers to any significant changes that may require further intervention.

In addition to providing practical information

and support, AI chatbots can offer emotional assistance to patients and their families. A cancer diagnosis can be overwhelming and emotionally challenging, and chatbots can provide a source of comfort by offering motivational messages, connecting users with support groups, and providing access to mental health resources. This emotional support can help alleviate some of the psychological burdens associated with cancer and improve the overall well-being of patients and their caregivers.

AI chatbots can also play a role in facilitating communication between patients and healthcare providers. They can help patients prepare for appointments by collecting relevant information and questions before the visit. This pre-appointment data ensures that healthcare providers have a complete picture of the patient's condition and concerns, leading to more focused and productive consultations. Additionally, chatbots can offer reminders for medication adherence, upcoming appointments, and follow-up care, helping patients stay engaged with their treatment plans.

Revolutionizing Access to Care Through Telemedicine

Telemedicine has revolutionized healthcare by enabling remote consultations and follow-up care, thus improving accessibility and convenience for patients. In the management of

urogenital cancers, telemedicine offers several key benefits, including enhanced access to specialized care, reduced travel burden, and improved management of chronic conditions.

One of the most significant advantages of telemedicine in urogenital cancer management is its ability to improve access to specialized care. Urogenital cancers often require the expertise of a multidisciplinary team, including urologists, oncologists, radiologists, and surgical specialists. Telemedicine allows patients to connect with these specialists without the need for extensive travel, which can be particularly beneficial for those living in remote or underserved areas. Virtual consultations enable patients to receive expert opinions, discuss treatment plans, and explore options for clinical trials or new therapies from the comfort of their homes.

The convenience of telemedicine also extends to follow-up care. Patients undergoing treatment for urogenital cancers often require regular check-ups to monitor their progress, manage side effects, and evaluate the effectiveness of their treatment. Telemedicine facilitates these follow-up visits, allowing patients to avoid frequent trips to the clinic while still receiving necessary care. This continuity of care can lead to better management of the disease and more timely adjustments to treatment plans.

Telemedicine supports the coordination of care among various healthcare providers. Urogenital

cancer treatment typically involves a team of specialists who need to collaborate closely to ensure comprehensive care. Telemedicine platforms enable seamless communication and collaboration among these professionals, facilitating case discussions, sharing of diagnostic images, and joint decision-making. This collaborative approach helps ensure that all aspects of the patient's care are integrated and aligned with their treatment goals.

Integrating AI Chatbots and Telemedicine for Comprehensive Care

The integration of AI chatbots with telemedicine creates a powerful synergy that enhances the overall management of urogenital cancers. By combining these technologies, healthcare providers can offer a more comprehensive and efficient care experience.

AI chatbots can be integrated into telemedicine platforms to provide patients with immediate assistance before, during, and after virtual consultations. For instance, chatbots can handle routine inquiries about appointment scheduling, provide pre-consultation instructions, and offer educational resources related to urogenital cancers. This functionality allows healthcare providers to focus on more complex aspects of care during virtual consultations, improving the overall efficiency of the care process.

During virtual consultations, chatbots can assist by gathering relevant information from patients and their families. This information can be used to prepare for the consultation, ensuring that the healthcare provider has a complete picture of the patient's condition and concerns. This pre-consultation data can lead to more focused and productive discussions during the virtual visit. Post-consultation, AI chatbots can provide follow-up support by reminding patients about medication schedules, monitoring symptoms, and addressing any additional questions or concerns. This continuous support helps patients stay engaged with their care plan and improves adherence to treatment recommendations.

Addressing Challenges and Considerations

While AI chatbots and telemedicine offer numerous benefits, there are several challenges and considerations that need to be addressed to ensure their effective implementation in the management of urogenital cancers.

Data privacy and security are major concerns when dealing with AI chatbots and telemedicine platforms. These technologies handle sensitive patient information, and it is crucial to implement robust security measures to protect this data from unauthorized access and breaches. Encryption, secure authentication, and regular security audits are essential to safeguarding patient information.

Accessibility is another important consideration. Not all patients may have access to the necessary technology or internet connectivity to use telemedicine services effectively. Additionally, some patients may have varying levels of comfort with digital tools. It is important to provide support and alternatives for those who may face barriers to using these technologies.

The accuracy and reliability of AI chatbots are also critical concerns. While chatbots can provide valuable information and support, there is always the risk of errors or misunderstandings. Continuous monitoring and updating of chatbot algorithms are necessary to ensure that they provide accurate and relevant information. Additionally, it is important to ensure that chatbots are designed to escalate complex or urgent issues to human healthcare providers when needed.

Future Directions and Innovations

The future of AI chatbots and telemedicine in the management of urogenital cancers holds exciting possibilities. As technology continues to advance, these tools are likely to become even more integrated into routine cancer care.

Advances in natural language processing and machine learning will enhance the capabilities of AI chatbots, allowing them to provide more personalized and accurate support. Future

chatbots may be able to analyze patient data in real-time to offer tailored recommendations and alerts, further improving patient care.

Telemedicine platforms will also continue to evolve, offering more advanced features and capabilities. Integration with wearable devices and remote monitoring tools could provide real-time data on patient health, allowing for more proactive management of urogenital cancers. Additionally, advancements in telecommunication technologies may improve the quality and reliability of virtual consultations.

Ongoing research and evaluation will be crucial in assessing the impact of AI chatbots and telemedicine on patient outcomes and healthcare delivery. Studies will help determine the effectiveness of these technologies in improving care, patient satisfaction, and overall quality of life for individuals with urogenital cancer.

Conclusion

AI chatbots and telemedicine represent significant advancements in the management of urogenital cancers. By enhancing patient support, improving access to care, and offering continuous monitoring, these technologies are transforming how urogenital cancer care is delivered. While there are challenges to address, the potential benefits of AI chatbots and telemedicine are substantial. As technology continues to evolve, these tools will play an increasingly

DR.MOHAMMAD-SOROUSHKHORSAND

important role in providing personalized, efficient, and compassionate care for individuals with urogenital cancer. The integration of AI chatbots and telemedicine into urogenital cancer management holds the promise of improved patient outcomes and a more streamlined and effective healthcare experience.

AI CHATBOTS AND TELEMEDICINE IN CANCER CARE: SU...

8- AI CHATBOTS AND TELEMEDICINE IN THE MANAGEMENT OF BONE CANCERS

Background

Bone malignancies are generally classified into two types: primary and secondary (metastatic) forms. Primary bone tumors, including osteosarcoma, chondrosarcoma, and Ewing sarcoma, make up the majority, constituting about two-thirds of cases. These tumors arise from primitive mesenchymal cells within the bone and represent nearly 0.2% of all cancer cases globally. Secondary bone tumors, on the other hand, develop when cancer from other parts of the body metastasizes to the bone.

Chemotherapy, surgical intervention, and radiotherapy are the principal treatment modalities. However, despite aggressive surgical efforts, complete tumor eradication is often unattainable, allowing for the possibility of metastasis and recurrence, which significantly raises mortality risks. Further complicating the situation, bone tumors frequently infiltrate vital bone structures, hindering the bone's natural self-repair mechanisms and greatly reducing patients' quality of life. As a result, addressing bone tumors and promoting bone regeneration in clinical

practice remains a formidable challenge.

In the age of precision oncology, imaging has become a cornerstone in the assessment and management of bone tumors. Diagnosing bone tumors via plain radiographs is a difficult task, even for experienced orthopedic surgeons and musculoskeletal radiologists. Human practitioners generally rely on "pattern recognition," analyzing factors such as the tumor's location, shape, size, density, and margin. Among these, the margin, or zone of transition, is particularly important. Benign tumors typically present with a narrow zone of transition, making them more visible on radiographs. In contrast, malignant bone tumors can evade detection unless there is clear evidence of radiolucency or cortical destruction. Tumors with osteoblastic or sclerotic characteristics, despite often having a narrow zone of transition, can sometimes be mistakenly identified as benign. Additionally, in patients with severe osteoporosis, the unclear borders of osteolytic tumors pose a heightened risk of misdiagnosis.

Radiomics, introduced in 2012, offers a novel approach to image analysis by enabling the automated extraction of numerous quantitative features from standard medical imaging with high throughput. The fundamental hypothesis of radiomics suggests that quantitative image analysis, facilitated by automated or semi-automatic software, can rapidly and consistently

provide clinicians with supplementary information, thereby aiding clinical decision-making.

Radiomics has advanced significantly alongside developments in computer-aided diagnostics, prognostication, treatment, and more. Significant efforts have been made to establish the utility and reliability of radiomics methodologies. Robust radiomics involves identifying a range of quantitative features from medical imaging, compiling this data into federated databases, and then using data-mining techniques to extract clinical insights. Medical images, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, are evaluated and processed to extract relevant radiomic features. These features are used in various aspects of bone tumor management, including screening, diagnosis, follow-up, prognosis, and pharmacokinetic and pharmacodynamic research.

Imaging-based signatures have thus emerged as powerful tools in precision oncology, particularly in the management of bone tumors. Radiomics seeks to leverage radiomic and other biomarkers to achieve the vision of "precision medicine," where accurate diagnoses and optimal treatments are tailored to individual patients and administered at the most appropriate time. Radiomic data holds the potential to guide biopsies, classify tumor grades, and predict prognosis and treatment

effectiveness. Significant progress has also been made in AI-driven analysis of plain radiographs. The observable characteristics used in bone tumor diagnosis, such as shape, matrix, density, and zone of transition, are well-suited for incorporation into deep learning algorithms.

The application of telemedicine, as an evolving medical tool, has become a significant milestone in healthcare worldwide in recent years. Telemedicine encompasses video conferencing, mobile apps, wearable devices, and other digital communication tools that can potentially facilitate healthcare service delivery, digital transformation, and continuous patient monitoring. Specifically in cancer management, notable advances in telemedicine have enabled healthcare professionals to provide services such as telegenetics counseling, which has been shown to be cost-effective and result in high patient satisfaction. Additionally, remote chemotherapy supervision, telepathology, and tele-education are among the many benefits of telemedicine.

In addition to telemedicine, AI chatbots have developed the capacity to enhance patient engagement and provide real-time medical assistance, offering medical consultations in specific circumstances. Large Language Models (LLMs) are employed to provide detailed information and simplify complex medical concepts, thereby offering more straightforward insights into treatment. In this context, we

will discuss the potential of telemedicine and AI chatbots in the management, treatment, diagnosis, and other aspects related to bone cancers.

Primary bone cancers, which include chondrosarcoma, osteosarcoma, and Ewing sarcoma, account for 7.70 cases per million individuals annually. These cancers are frequently characterized by localized or regional pain and restricted range of motion. However, due to the delayed onset of symptoms and their similarity to typical musculoskeletal injuries, early diagnosis remains challenging. Moreover, a significant number of cases present with lung metastasis at the time of diagnosis. Therefore, the integration of AI chatbots and telemedicine can play a crucial role in managing these conditions.

In this regard, mobile applications create an interactive environment between patients and healthcare professionals. A mobile health management system has been suggested, focusing on tracking patients with musculoskeletal malignancies following surgery. During the COVID-19 pandemic, the use of telemedicine and smartphones became even more valuable, as seen in the case of a 4-year-old patient with Ewing sarcoma who benefited from telemedicine consultations. Studies have found a positive relationship between post-operative rehabilitation services and surgical outcomes. Telerehabilitation can improve the quality of life

and engagement of cancer patients by managing symptoms, offering skilled therapies, providing physiatry services, facilitating support groups, and implementing exercise-based interventions. Consequently, patients may experience better outcomes following surgery. The use of telehealth was popular among both patients and healthcare professionals during the COVID-19 pandemic.

Bone cancers present significant clinical challenges related to diagnosis, treatment selection, and prognostication. The management of bone cancers traditionally involves a multidisciplinary approach that integrates surgery, chemotherapy, and radiation therapy. However, the prognosis varies depending on histopathology, staging, and patient-specific factors. Recently, there has been growing interest in using artificial intelligence algorithms and telemedicine technologies for bone cancer treatment. These innovative solutions have the potential to enhance patient education initiatives, facilitate remote monitoring of symptoms, and enable the creation of individualized treatment plans. This chapter explores the role of AI assistants and telehealth in bone cancer management and their ability to influence clinical outcomes.

Artificial intelligence chatbots and telemedicine have emerged as promising approaches with the power to reshape the delivery of medical services. AI chatbots are equipped

with intelligent technologies that can understand natural language, allowing them to communicate effectively with users. Through natural conversation, chatbots can interact with patients, comprehend their questions, and provide helpful information, guidance, and support. Telemedicine, on the other hand, involves offering health services remotely using technologies such as video calls and remote monitoring devices. This allows healthcare providers to evaluate, diagnose, and treat patients regardless of physical proximity, eliminating distance as a barrier to care and improving access to treatment. When implemented judiciously, these technologies hold promise for enhancing patient outcomes, streamlining healthcare systems, and reducing costs. They may increase patient involvement, reduce unnecessary clinic visits, and allow clinicians to provide care to a larger population. A widespread but thoughtful adoption of these technologies could transform public health by improving access to high-quality, compassionate care when and where it is needed most.

AI chatbots have great potential to support bone cancer treatment. The support, knowledge, and personalized attention they can offer to patients and medical staff could make a substantial difference. AI assistants can act as virtual companions, providing educational materials and answering questions about bone cancer. Chatbots can share information about treatment options,

potential side effects, and self-care strategies. By offering patients customized, accurate information, chatbots empower them to make informed choices about their care journey. These intelligent programs can also assist in monitoring symptoms and alerting healthcare providers to any concerning changes. Through regular check-ins, chatbots can collect information such as pain levels, functional difficulties, or side effects of treatment. Doctors can then analyze this data using machine learning algorithms to identify patterns and potentially detect issues earlier, allowing for swift action.

By studying a patient's medical history, response to different therapies, and genetic profile, AI assistants can provide personalized recommendations based on evidence-based guidelines. This approach helps treatment teams tailor care plans to the individual, which may improve outcomes and reduce unnecessary procedures. Bone cancer can have a profound emotional impact on patients and their loved ones. Chatbots can offer emotional support through empathetic responses, sharing coping strategies, and connecting patients to relevant support networks. This assistance may help alleviate anxiety and enhance mental well-being throughout the cancer experience.

Tele-rehabilitation provides an opportunity to deliver rehabilitative services remotely using telecommunication technologies. This modality

has shown potential in addressing the physical impairments and limitations in functional mobility often experienced by individuals undergoing treatment for bone cancers. Through tele-rehabilitation, patients can access personalized exercise programs, guidance on physical therapy regimens, and progress monitoring within the comfort of their homes.

In conclusion, artificial intelligence holds significant promise in supporting both patients and healthcare providers. The advances in AI assistants and telehealth offer new opportunities for improving bone cancer treatment approaches. With further refinements in conversational abilities, data integration, and decision-making support, intelligent chatbots have the potential to provide customized recommendations and guidance. Additionally, the development of remote monitoring and virtual technology through telemedicine platforms could enhance remote care delivery. Continued research and practical applications are needed to fully realize the capabilities of AI chatbots and telemedicine in managing bone cancer. With ongoing refinement, these emerging strategies offer great hope for supporting patients and practitioners in confronting this condition. Further efforts can help achieve a future of networked, personalized, and empowering care.

The Role of AI in the

Management of Primary Bone Tumors

In 2016, bone and joint cancer was the third most common cause of cancer-related deaths among individuals under 20 years old in the United States, with approximately 3,500 new bone cancer cases diagnosed in 2019. Benign bone tumors typically have limited potential for local recurrence and are usually treated through complete local excision or curettage. In contrast, malignant bone tumors not only exhibit locally invasive growth and recurrence but also pose a significant risk for distant metastases.

Bone biopsy is often performed in patients with benign tumors, a procedure that can lead to increased morbidity, higher costs, and potential sampling inaccuracies. Therefore, an algorithm capable of differentiating between benign and malignant bone tumors using radiological imaging could guide patient care, streamline the triage process, and prevent unnecessary interventions.

Artificial intelligence (AI) algorithms, particularly those utilizing deep learning (DL) techniques, have made remarkable progress in image recognition tasks. Methods such as convolutional neural networks (CNNs) and variational autoencoders have been widely employed in medical image analysis, advancing the field at a rapid pace.

Jie Li et al. conducted a study demonstrating that the "You Only Look Once" deep learning

(YOLO DL) model could automatically detect bone tumors from full-field radiographs in a single shot and classify images as normal, benign, intermediate, or malignant. Similarly, Yu He et al. used conventional radiographs to develop a DL model for classifying primary bone tumors. Claudio E. von Schacky et al. introduced a machine learning model to distinguish between benign and malignant bone tumors and found that, while its accuracy was lower than that of specialized radiologists, it was comparable or superior to that of residents.

Sarah Consalvo et al. developed an algorithm for differentiating between Ewing sarcoma and osteomyelitis in children based on radiographs. Ewing sarcoma is the second most common bone tumor in childhood and adolescence, known for its high aggressiveness. They claimed that their AI algorithm serves as an advantageous tool for detecting and distinguishing between these diseases.

On the other hand, some researchers have developed DL models based on magnetic resonance imaging (MRI) for detecting and classifying bone tumors. Feyisope R. Eweje et al. reported that MRI-based DL can effectively differentiate between benign and malignant bone tumors. Additionally, Vlad Alexandru Georgeanu et al. developed a DL algorithm for diagnosing malignant bone tumors and demonstrated its effectiveness and value in this context.

The Role of AI in the Management of Bone Metastasis

Tumor metastasis, including lymph node metastasis (LNM) and distant metastasis (DM), significantly contributes to cancer-related mortality. Therefore, conducting a thorough and precise preoperative work-up for metastasis is crucial.

Simin Liu et al. implemented a DL model for analyzing bone metastases (BMs) on bone scintigrams, demonstrating that using DL within automated analysis frameworks can effectively detect BMs. Furthermore, Qiuhan Zheng et al., in their meta-analysis, concluded that AI algorithms have the potential to diagnose metastases based on medical radiology imaging with accuracy comparable to or even superior to that of healthcare professionals. This finding lays the groundwork for the clinical utilization of AI in this setting.

The Role of AI in the Management of Spinal Bone Tumors

Spinal tumors include both benign and malignant entities, potentially resulting in spine fractures and neurological deficits. However, acquiring the diagnostic expertise to differentiate between various spinal tumors using MRI scans poses challenges for junior radiologists and

orthopedists, highlighting the utility of deep learning in this context.

Salvatore Gitto et al. concluded that support vector machine (SVM) classifiers, leveraging radiomic characteristics derived from T2- and diffusion-weighted imaging, show promise in categorizing spinal tumors. Moreover, Vito Chianca et al. evaluated the diagnostic efficacy of machine learning (ML) in distinguishing different spinal lesions, illustrating that combining MRI radiomics with an ML model could enhance spinal lesion evaluation.

Additionally, Hong Liu et al. introduced a novel multi-model weighted fusion framework (WFF) based on MRI and age data, demonstrating that WFF is valuable for diagnosing histologically complex spinal tumors using MRI technology.

9- AI CHATBOTS AND TELEMEDICINE IN THE MANAGEMENT OF OTHER CANCERS

AI Chatbots and Telemedicine in the Management of Hematological Cancers

Hematological cancers, including leukemia, lymphoma, and myeloma, represent a diverse group of malignancies affecting the blood, bone marrow, and lymphatic system. Managing these cancers involves complex and often prolonged treatment regimens, necessitating a multidisciplinary approach to care. The integration of artificial intelligence (AI) chatbots and telemedicine into the management of hematological cancers is reshaping the landscape of oncology, offering new avenues for improving patient outcomes, enhancing care efficiency, and supporting healthcare professionals.

The Role of AI Chatbots in Hematological Cancer Management

AI chatbots have emerged as innovative tools in healthcare, leveraging advancements in natural language processing (NLP) and machine learning

to provide support and information to patients and healthcare providers. In the context of hematological cancers, chatbots can serve multiple functions, from patient education to symptom monitoring and emotional support.

One of the primary uses of AI chatbots in hematological cancer management is patient education. Patients diagnosed with hematological cancers often face a steep learning curve regarding their condition, treatment options, and potential side effects. AI chatbots can provide clear, accurate, and personalized information about these aspects. For instance, chatbots can explain the differences between various types of leukemia or lymphoma, outline the goals of treatment, and describe the expected side effects of chemotherapy or targeted therapy. This educational support helps patients better understand their condition and participate more actively in their treatment decisions.

In addition to education, AI chatbots play a crucial role in symptom management. Hematological cancers and their treatments can lead to a wide range of symptoms, including fatigue, anemia, infection risk, and bleeding complications. Chatbots can assist patients in tracking these symptoms and provide guidance on managing them. For example, a chatbot might offer advice on managing side effects like nausea or suggest ways to cope with fatigue. By continuously collecting

and analyzing data on patient symptoms, chatbots can alert healthcare providers to any significant changes that may require further investigation or intervention.

AI chatbots also offer valuable emotional support to patients and their families. A cancer diagnosis can be emotionally overwhelming, and chatbots can provide a source of comfort and encouragement. They can offer motivational messages, connect patients with support groups or counseling services, and provide information on coping strategies and mental health resources. This emotional support helps alleviate some of the psychological burdens associated with cancer and improves the overall well-being of patients.

Moreover, chatbots can facilitate communication between patients and healthcare providers. They can help patients prepare for appointments by collecting relevant information and questions before the visit, ensuring that healthcare providers have a comprehensive understanding of the patient's condition and concerns. Chatbots can also provide reminders for medication adherence, upcoming appointments, and follow-up care, helping patients stay engaged with their treatment plans.

Telemedicine and Its Impact on Hematological Cancer Care

Telemedicine has become an integral part

of modern healthcare, offering patients the ability to consult with healthcare providers remotely. In the management of hematological cancers, telemedicine provides several key benefits, including improved access to specialized care, reduced travel burden, and enhanced management of chronic conditions.

One of the primary advantages of telemedicine in hematological cancer care is its ability to enhance access to specialized care. Hematological cancers often require the expertise of hematologists, oncologists, and other specialists. Telemedicine allows patients to connect with these experts without the need for extensive travel, which is especially beneficial for those living in remote or underserved areas. Virtual consultations enable patients to receive expert opinions, discuss treatment options, and explore clinical trials or new therapies from the comfort of their homes.

Telemedicine also plays a crucial role in follow-up care. Patients undergoing treatment for hematological cancers often require regular monitoring to assess treatment efficacy, manage side effects, and address any complications. Telemedicine facilitates these follow-up visits, allowing patients to avoid frequent trips to the clinic while still receiving necessary care. This continuity of care can lead to better management of the disease and more timely adjustments to treatment plans.

In addition to improving access and convenience, telemedicine supports the coordination of care among various healthcare providers. Hematological cancer treatment typically involves a multidisciplinary team, including hematologists, oncologists, nurses, and supportive care specialists. Telemedicine platforms enable seamless communication and collaboration among these professionals, facilitating case discussions, sharing of diagnostic information, and joint decision-making. This collaborative approach helps ensure that all aspects of the patient's care are integrated and aligned with their treatment goals.

Integrating AI Chatbots with Telemedicine for Enhanced Care

The integration of AI chatbots with telemedicine platforms creates a synergistic approach that enhances the overall management of hematological cancers. By combining these technologies, healthcare providers can offer a more comprehensive and efficient care experience.

AI chatbots can be integrated into telemedicine platforms to provide patients with immediate assistance before, during, and after virtual consultations. For example, chatbots can handle routine inquiries about appointment scheduling, provide pre-consultation instructions, and offer educational resources related to hematological

cancers. This functionality allows healthcare providers to focus on more complex aspects of care during virtual consultations, improving the overall efficiency of the care process.

During virtual consultations, chatbots can assist by gathering relevant information from patients and their families. This pre-consultation data ensures that healthcare providers have a complete picture of the patient's condition and concerns, leading to more focused and productive discussions during the virtual visit.

Post-consultation, AI chatbots can provide follow-up support by reminding patients about medication schedules, monitoring symptoms, and addressing any additional questions or concerns. This continuous support helps patients stay engaged with their care plan and improves adherence to treatment recommendations.

Challenges and Considerations

While AI chatbots and telemedicine offer numerous benefits, there are several challenges and considerations that need to be addressed to ensure their effective implementation in the management of hematological cancers.

Data privacy and security are major concerns when dealing with AI chatbots and telemedicine platforms. These technologies handle sensitive patient information, and it is crucial to implement robust security measures to protect this data from

unauthorized access and breaches. Encryption, secure authentication, and regular security audits are essential to safeguarding patient information.

Accessibility is another important consideration. Not all patients may have access to the necessary technology or internet connectivity to use telemedicine services effectively. Additionally, some patients may have varying levels of comfort with digital tools. It is important to provide support and alternatives for those who may face barriers to using these technologies.

The accuracy and reliability of AI chatbots are also critical concerns. While chatbots can provide valuable information and support, there is always the risk of errors or misunderstandings. Continuous monitoring and updating of chatbot algorithms are necessary to ensure that they provide accurate and relevant information. Additionally, it is important to ensure that chatbots are designed to escalate complex or urgent issues to human healthcare providers when needed.

Future Directions and Innovations

The future of AI chatbots and telemedicine in the management of hematological cancers holds exciting possibilities. As technology continues to advance, these tools are likely to become even more integrated into routine cancer care.

Advances in natural language processing and machine learning will enhance the capabilities of AI chatbots, allowing them to provide more personalized and accurate support. Future chatbots may be able to analyze patient data in real-time to offer tailored recommendations and alerts, further improving patient care.

Telemedicine platforms will also continue to evolve, offering more advanced features and capabilities. Integration with wearable devices and remote monitoring tools could provide real-time data on patient health, allowing for more proactive management of hematological cancers. Additionally, advancements in telecommunication technologies may improve the quality and reliability of virtual consultations.

Ongoing research and evaluation will be crucial in assessing the impact of AI chatbots and telemedicine on patient outcomes and healthcare delivery. Studies will help determine the effectiveness of these technologies in improving care, patient satisfaction, and overall quality of life for individuals with hematological cancer.

Conclusion

AI chatbots and telemedicine represent significant advancements in the management of hematological cancers. By enhancing patient support, improving access to care, and offering continuous monitoring, these technologies are

transforming how hematological cancer care is delivered. While there are challenges to address, the potential benefits of AI chatbots and telemedicine are substantial. As technology continues to evolve, these tools will play an increasingly important role in providing personalized, efficient, and compassionate care for individuals with hematological cancer. The integration of AI chatbots and telemedicine into hematological cancer management holds the promise of improved patient outcomes and a more streamlined and effective healthcare experience.

Legal Frameworks and Patient Rights in AI-Driven Telemedicine for Cancer Care

Background

The advent of AI-powered chatbots and telemedicine in cancer care has created significant opportunities for patient engagement, improved efficiency, and enhanced accessibility to healthcare services. However, the rapid expansion of these technologies has also raised various legal concerns, particularly regarding patients' rights. This narrative review focuses on the intricate legal structures surrounding AI and telemedicine in the United States, with a particular emphasis on the rights of patients within this evolving context.

Regulatory Landscape

One of the most authoritative laws governing patient data in the United States is the Health Insurance Portability and Accountability Act (HIPAA). HIPAA imposes strict regulations to protect patients' health information (PHI), emphasizing both confidentiality and security. According to HIPAA's Privacy Rule, healthcare providers must implement adequate security measures to prevent unauthorized exposure of PHI, while the Security Rule mandates the protection of electronic PHI (ePHI) through methods such as encryption and access control.

In addition to HIPAA, the Food and Drug Administration (FDA) plays a critical role in regulating AI use in medical devices and telemedicine procedures. The FDA governs the safety and efficacy of AI technologies in healthcare by enforcing standards through pre-market approval, where AI algorithms are evaluated for accuracy and risk reduction, and post-market surveillance, where algorithms are continuously monitored to prevent incidents from reoccurring.

Furthermore, the Centers for Medicare & Medicaid Services (CMS) have established policies that significantly influence the use of telemedicine in cancer treatment. CMS offers reimbursement for telehealth services, promoting their application in home consultations and follow-ups. CMS quality

measures also aim to deliver excellent service quality in telemedicine, protecting patient health while fostering positive clinical outcomes.

Informed Consent

Legal Requirements for Informed Consent

Informed consent is a foundational legal principle that affirms a patient's autonomy in the healthcare treatment process, particularly with the rise of AI and telemedicine. Patients must be fully informed about the nature, benefits, and risks of the proposed treatment. This includes clear disclosures regarding AI algorithm usage, ensuring that AI systems provide upfront, self-explanatory information about their capabilities and limitations, as outlined by Ridge (2020). Informed consent requires that patients comprehend the information provided and voluntarily agree to the treatment plans.

Specific Implementations of AI and Telemedicine

AI and telemedicine have introduced new complexities regarding informed consent. Patients must be informed about how their data will be utilized, managed, and shared, with a strong emphasis on data protection. Additionally, any recommendations made by AI systems in

healthcare must include a disclosure of potential risks, allowing patients to make well-informed decisions regarding their treatment.

Privacy and Data Security

Data Protection Laws

Telemedicine platforms and AI systems must comply with HIPAA to ensure the privacy of patient information. Healthcare institutions are required to implement robust measures to safeguard health data. This compliance also involves adhering to state-level statutes, such as the California Consumer Privacy Act (CCPA), which provides additional protections for patients' personal information.

Security Measures

Since patient data is often transmitted over the internet in AI and telemedicine platforms, rigorous security standards must be adopted to safeguard this information. Data should be encrypted before transmission or storage to ensure secure communication, and access controls should be in place to prevent unauthorized access. Moreover, audit trails are essential for tracking data usage, identifying potential violations, and providing accountability for any data breaches.

Patient Rights

Right to Access and Control

Patients, or the individuals to whom the information pertains, are entitled to certain rights, including the ability to make specific requests concerning their health data. This includes the right to correct inaccuracies in their records, ensuring that they have access to accurate and up-to-date health information. By maintaining these legal frameworks and respecting patients' rights, AI-driven telemedicine can continue to advance while ensuring patient safety, privacy, and autonomy.

Right to Privacy

The protection of patient information is both a legal and ethical obligation in the application of artificial intelligence (AI) and telemedicine. Ensuring patient confidentiality and safeguarding patients' identifiable information are paramount. It is possible to maintain privacy while collecting anonymized data, which enhances the utility of big data in AI systems without compromising patient privacy.

Right to Be Informed

Patients have the right to be informed about how specific AI algorithms influence their care. Transparency in the peer review of algorithms and the reasoning behind the system's outcomes must

be communicated to patients to foster trust in these technologies. The supervision of AI systems is essential to ensure that the recommendations provided are clinically appropriate and to safeguard patient safety.

Legal Problems and Ethical Issues

Algorithmic Bias

Algorithmic bias presents a significant issue in the implementation of AI. Bias within AI algorithms can result in disparities in care, disproportionately affecting certain patient populations. Addressing this bias is not only an ethical responsibility but also a legal requirement to guarantee equitable treatment for all patients.

Liability Issues

Determining liability in AI and telemedicine presents a complex challenge. Medical malpractice claims, traditionally centered around negligent care, may arise in cases where AI plays a role in patient management. Conversely, defects or malfunctions in the AI technology fall under product liability laws, holding the creators of the technology accountable. Clear legal guidelines must be established to define the roles and responsibilities of individuals and entities involved, ensuring accountability.

Ethical Dilemmas

The use of AI and telemedicine in cancer care also raises significant ethical concerns. Core ethical principles such as patient autonomy, fairness, justice, and equitable access to care must be carefully considered. Ensuring that no disparities arise in access to AI and telemedicine services is critical to uphold these ethical standards.

Conclusion

The integration of AI chatbots and telemedicine into cancer treatment offers immense potential to improve the quality of patient care and treatment outcomes. However, these advancements also bring with them complex legal and ethical challenges. Effective legislation, combined with vigilant oversight by patient advocacy groups, is essential to ensure the responsible implementation of AI and telemedicine. When properly regulated, these technologies can significantly enhance access to healthcare without infringing upon patient rights.

Additional Considerations

Case Law

The inclusion of case law provides valuable insights into the legal issues surrounding AI and telemedicine. Examining relevant cases can offer guidance on navigating the legal landscape and

identifying potential risks.

Patient Advocacy Groups

Non-governmental organizations and patient advocacy groups play a crucial role in protecting patients' rights and influencing policy changes. These groups advocate for actions that safeguard patients and promote responsible use of technology in healthcare delivery.

Legal Resources

Sharing recommended approaches and providing access to a variety of legal resources and organizations can benefit both healthcare patients and practitioners in dealing with AI and telemedicine. Resources such as legal assistance providers, government agencies, and professional organizations can offer support and intervention in addressing legal challenges. By exploring the legal issues and patients' rights in AI-driven telemedicine for cancer care, this study aims to provide a comprehensive understanding of regulatory frameworks and emphasize the importance of safeguarding patient rights in the advancement of telemedicine.

AI Chatbots and Telemedicine in the Management of Ophthalmological Cancers

Cancers affecting the eye can impair vision and

pose life-threatening risks. Although these tumors are relatively uncommon and diverse, they are the only ocular diseases that directly endanger life through invasion or metastasis to other organs. Therefore, accurate diagnosis and timely treatment are crucial. Malignant ophthalmic tumors may present as intraocular neoplasms, such as uveal melanoma, retinoblastoma, and intraocular lymphoma, or as periocular tumors, including basal cell carcinoma, squamous cell carcinoma, and sebaceous gland carcinoma.

Uveal melanoma, the most common primary eye tumor in adults, typically occurs in the iris, ciliary body, or choroid. Recent advancements in early detection offer hope for improved survival rates, as smaller tumors can now be managed more effectively. Timely identification and treatment are essential for favorable long-term outcomes in uveal melanoma. The primary goal of uveal melanoma treatment is to preserve the eye and functional vision while reducing the risk of metastasis when possible.

Retinoblastoma is the most prevalent ocular tumor in pediatric patients, presenting as a rare form of cancer that specifically affects the retinas of infants. It is the most common eye cancer in childhood and can be fatal if not treated promptly. Intraocular lymphoma presents in two distinct forms: one originates within the central nervous system (CNS), known as primary CNS lymphoma,

while the other develops outside the CNS and subsequently metastasizes to the eye.

Recent advancements in artificial intelligence and telemedicine have significantly transformed healthcare, especially in managing diseases like eye cancers. Telemedicine involves the practical application of data collection and utilization for research purposes, playing a pivotal role in studying diseases and providing treatment through data storage and essential services. Its principal aim is to ensure universal healthcare access by delivering high-quality care to cancer patients and facilitating real-time interactions to access disease-related information. Additionally, telemedicine strengthens screening and diagnosis in underserved regions.

Another technology that may aid in cancer management within telemedicine is AI-based chatbots. Chatbots, which use advanced machine learning (ML) and deep learning (DL) techniques, mimic human conversation to provide personalized, immediate responses in the field of telemedicine. These AI-driven systems enhance patient care by facilitating continuous monitoring and follow-up, particularly in eye cancer treatment, where timely and precise interaction is essential for effective management and improved patient outcomes.

Maximizing the potential benefits of these technologies requires addressing

several challenges. Significant investment and technological improvements are needed to integrate AI into existing telemedicine platforms. Concerns about data privacy and the necessity of strong cybersecurity measures to protect sensitive patient information warrant careful consideration. Additionally, ensuring equitable access to AI-powered telemedicine services is a considerable challenge, particularly in underserved areas. This chapter explores how chatbots and telemedicine can revolutionize eye cancer care, highlighting both the benefits and challenges of this integration.

REFERENCES

1. Agrawal S, Vagha S. A Comprehensive Review of Artificial Intelligence in Prostate Cancer Care: State-of-the-Art Diagnostic Tools and Future Outlook. *Cureus*. 2024;16(8):e66225.
2. Ahervo H, Korhonen J, Lim Wei Ming S, Guan Yunqing F, Soini M, Lian Pei Ling C, et al. Artificial intelligence-supported applications in head and neck cancer radiotherapy treatment planning and dose optimisation. *Radiography (Lond)*. 2023;29(3):496-502.
3. Ahn JS, Shin S, Yang SA, Park EK, Kim KH, Cho SI, et al. Artificial Intelligence in Breast Cancer Diagnosis and Personalized Medicine. *J Breast Cancer*. 2023;26(5):405-35.
4. Akin O, Lema-Dopico A, Paudyal R, Konar AS, Chenevert TL, Malyarenko D, et al. Multiparametric MRI in Era of Artificial Intelligence for Bladder Cancer Therapies. *Cancers (Basel)*. 2023;15.(22)
5. Al Muhaisen S, Safi O, Ulayan A, Aljawamis S, Fakhoury M, Baydoun H, et al. Artificial Intelligence-Powered Mammography: Navigating the Landscape of Deep Learning for Breast Cancer Detection. *Cureus*. 2024;16(3):e56945.
6. Al-Kadi OS, Al-Emaryeen R, Al-Nahhas S, Almallaahi I, Braik R, Mahafza W. Empowering brain cancer diagnosis: harnessing artificial intelligence for advanced imaging insights. *Rev Neurosci*. 2024;35(4):399-419.
7. Alabi RO, Elmusrati M, Leivo I, Almangush A, Mäkitie AA. Artificial Intelligence-Driven Radiomics in Head and Neck Cancer: Current Status and Future Prospects. *Int J Med Inform*. 2024;188:105464.
8. Ali H, Qureshi R, Shah Z. Artificial Intelligence-Based Methods for Integrating Local and Global Features for Brain Cancer Imaging: Scoping Review. *JMIR Med Inform*. 2023;11:e47445.
9. Ameen A, Shaikh K, Khan A, Vohra LM. The discerning influence of dynamic contrast-enhanced MRI in anticipating molecular subtypes of breast cancer through the artistry of artificial intelligence - a narrative review. *J Pak Med Assoc*. 2024;74(4 (Supple-4)):S72-s8.
10. Aswathy R, Sumathi S. The Evolving Landscape of Cervical Cancer: Breakthroughs in Screening and Therapy Through Integrating Biotechnology and Artificial Intelligence. *Mol Biotechnol*. 2024.
11. Avella P, Cappuccio M, Cappuccio T, Rotondo M, Fumarulo D, Guerra G, et al. Artificial Intelligence to Early Predict Liver Metastases in Patients with Colorectal Cancer: Current Status and Future Perspectives. *Life (Basel)*. 2023;13.(10)
12. Azadi Moghadam P, Bashashati A, Goldenberg SL. Artificial Intelligence and Pathomics: Prostate Cancer. *Urol Clin North Am*.

2024;51(1):15-26.

13. Bassani S, Lee YK, Campagnari V, Eccher A, Monzani D, Nocini R, et al. From Hype To Reality: A Narrative Review on the Promising Role of Artificial Intelligence in Larynx Cancer Detection and Transoral Microsurgery. *Crit Rev Oncog.* 2023;28(3):21-4.

14. Bassi M, Vaz Sousa R, Zacchini B, Centofanti A, Ferrante F, Poggi C, et al. Lung Cancer Surgery in Octogenarians: Implications and Advantages of Artificial Intelligence in the Preoperative Assessment. *Healthcare (Basel).* 2024;12.(7)

15. Batool Z, Kamal MA, Shen B. Advancements in triple-negative breast cancer sub-typing, diagnosis and treatment with assistance of artificial intelligence : a focused review. *J Cancer Res Clin Oncol.* 2024;150(8):383.

16. Baydoun A, Jia AY, Zaorsky NG, Kashani R, Rao S, Shoag JE, et al. Artificial intelligence applications in prostate cancer. *Prostate Cancer Prostatic Dis.* 2024;27(1):37-45.

17. Bazarkin A, Morozov A, Androsov A, Fajkovic H, Rivas JG, Singla N, et al. Assessment of Prostate and Bladder Cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review. *Curr Urol Rep.* 2024;25(1):19-35.

18. Boland PA, Hardy NP, Moynihan A, McEntee PD, Loo C, Fenlon H, et al. Intraoperative near infrared functional imaging of rectal cancer using artificial intelligence methods - now and near future state of the art. *Eur J Nucl Med Mol Imaging.*

2024;51(10):3135-48.

19. Brancaccio G, Balato A, Malveyh J, Puig S, Argenziano G, Kittler H. Artificial Intelligence in Skin Cancer Diagnosis: A Reality Check. *J Invest Dermatol.* 2024;144(3):492-9.

20. Breen J, Allen K, Zucker K, Adusumilli P, Scarsbrook A, Hall G, et al. Artificial intelligence in ovarian cancer histopathology: a systematic review. *NPJ Precis Oncol.* 2023;7(1):83.

21. Bulashevskaya A, Nacsza Z, Lang F, Braun M, Machyna M, Diken M, et al. Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy. *Front Immunol.* 2024;15:1394003.

22. Butt SR, Soulat A, Lal PM, Fakhor H, Patel SK, Ali MB, et al. Impact of artificial intelligence on the diagnosis, treatment and prognosis of endometrial cancer. *Ann Med Surg (Lond).* 2024;86(3):1531-9.

23. Calderaro J, Žigutytė L, Truhn D, Jaffe A, Kather JN. Artificial intelligence in liver cancer - new tools for research and patient management. *Nat Rev Gastroenterol Hepatol.* 2024;21(8):585-99.

24. Carter SM, Popic D, Marinovich ML, Carolan L, Houssami N. Women's views on using artificial intelligence in breast cancer screening: A review and qualitative study to guide breast screening services. *Breast.* 2024;77:103783.

25. Castellani D, Perpepaj L, Fuligni D, Chiacchio G, Tramanzoli P, Stramucci S, et al.

Advancements in artificial intelligence for robotic-assisted radical prostatectomy in men suffering from prostate cancer: results from a scoping review. *Chin Clin Oncol.* 2024;13(4):54.

26. Cellina M, Cacioppa LM, Cè M, Chiarpenello V, Costa M, Vincenzo Z, et al. Artificial Intelligence in Lung Cancer Screening: The Future Is Now. *Cancers (Basel).* 2023;15.(17)

27. Cellina M, De Padova G, Caldarelli N, Libri D, Cè M, Martinenghi C, et al. Artificial Intelligence in Lung Cancer Imaging: From Data to Therapy. *Crit Rev Oncog.* 2024;29(2):1-13.

28. Chaddad A, Tan G, Liang X, Hassan L, Rathore S, Desrosiers C, et al. Advancements in MRI-Based Radiomics and Artificial Intelligence for Prostate Cancer: A Comprehensive Review and Future Prospects. *Cancers (Basel).* 2023;15.(15)

29. Chang CT, Daneshjou R. Disentangling Hype from Reality for Artificial Intelligence-Based Skin Cancer Diagnosis: Comment on a Narrative Review. *J Invest Dermatol.* 2024;144(3):444-5.

30. Chapla D, Chorya HP, Ishfaq L, Khan A, Vr S, Garg S. An Artificial Intelligence (AI)-Integrated Approach to Enhance Early Detection and Personalized Treatment Strategies in Lung Cancer Among Smokers: A Literature Review. *Cureus.* 2024;16(8):e66688.

31. Chen M, Copley SJ, Viola P, Lu H, Aboagye EO. Radiomics and artificial intelligence for precision medicine in lung cancer treatment. *Semin Cancer Biol.* 2023;93:97-113.

32. Cheng H, Xu H, Peng B, Huang X, Hu Y, Zheng C, et al. Illuminating the future of precision cancer surgery with fluorescence imaging and artificial intelligence convergence. *NPJ Precis Oncol.* 2024;8(1):196.

33. Choi S, Kim S. Artificial Intelligence in the Pathology of Gastric Cancer. *J Gastric Cancer.* 2023;23(3):410-27.

34. Chugh V, Basu A, Kaushik A, Manshu, Bhansali S, Basu AK. Employing nano-enabled artificial intelligence (AI)-based smart technologies for prediction, screening, and detection of cancer. *Nanoscale.* 2024;16(11):5458-86.

35. Cobanaj M, Corti C, Dee EC, McCullum L, Boldrini L, Schlam I, et al. Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow. *Eur J Cancer.* 2024;198:113504.

36. Dang A, Dang D, Vallish BN. Extent of use of artificial intelligence & machine learning protocols in cancer diagnosis: A scoping review. *Indian J Med Res.* 2023;157(1):11-22.

37. Danishuddin, Khan S, Kim JJ. From cancer big data to treatment: Artificial intelligence in cancer research. *J Gene Med.* 2024;26(1):e3629.

38. Das K, Paltani M, Tripathi PK, Kumar R, Verma S, Kumar S, et al. Current implications and challenges of artificial intelligence technologies in therapeutic intervention of

colorectal cancer. *Explor Target Antitumor Ther.* 2023;4(6):1286-300.

39. Derbal Y. Adaptive Cancer Therapy in the Age of Generative Artificial Intelligence. *Cancer Control.* 2024;31:10732748241264704.

40. Devault-Tousignant C, Harvie M, Bissada E, Christopoulos A, Tabet P, Guertin L, et al. The use of artificial intelligence in reconstructive surgery for head and neck cancer: a systematic review. *Eur Arch Otorhinolaryngol.* 2024.

41. Di Costanzo G, Ascione R, Ponsiglione A, Tucci AG, Dell'Aversana S, Iasiello F, et al. Artificial intelligence and radiomics in magnetic resonance imaging of rectal cancer: a review. *Explor Target Antitumor Ther.* 2023;4(3):406-21.

42. Díaz O, Rodríguez-Ruíz A, Sechopoulos I. Artificial Intelligence for breast cancer detection: Technology, challenges, and prospects. *Eur J Radiol.* 2024;175:111457.

43. Efstathiou E, Merseburger A, Liew A, Kurtyka K, Panda O, Dalechek D, et al. Perception of cure in prostate cancer: human-led and artificial intelligence-assisted landscape review and linguistic analysis of literature, social media and policy documents. *ESMO Open.* 2024;9(5):103007.

44. Elahi R, Nazari M. An updated overview of radiomics-based artificial intelligence (AI) methods in breast cancer screening and diagnosis. *Radiol Phys Technol.* 2024.

45. Faa G, Coghe F, Pretta A, Castagnola M, Van Eyken P, Saba L, et al. Artificial Intelligence Models

for the Detection of Microsatellite Instability from Whole-Slide Imaging of Colorectal Cancer. *Diagnostics (Basel).* 2024;14.(15)

46. Faur AC, Lazar DC, Ghenciu LA. Artificial intelligence as a noninvasive tool for pancreatic cancer prediction and diagnosis. *World J Gastroenterol.* 2023;29(12):1811-23.

47. Fawaz A, Ferraresi A, Isidoro C. Systems Biology in Cancer Diagnosis Integrating Omics Technologies and Artificial Intelligence to Support Physician Decision Making. *J Pers Med.* 2023;13.(11)

48. Ferro M, Falagario UG, Barone B, Maggi M, Crocetto F, Busetto GM, et al. Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement. *Diagnostics (Basel).* 2023;13.(13)

49. Foltz EA, Witkowski A, Becker AL, Latour E, Lim JY, Hamilton A, et al. Artificial Intelligence Applied to Non-Invasive Imaging Modalities in Identification of Nonmelanoma Skin Cancer: A Systematic Review. *Cancers (Basel).* 2024;16.(3)

50. Franzese C, Dei D, Lambri N, Teriaca MA, Badalamenti M, Crespi L, et al. Enhancing Radiotherapy Workflow for Head and Neck Cancer with Artificial Intelligence: A Systematic Review. *J Pers Med.* 2023;13.(6)

51. Frascarelli C, Bonizzi G, Musico CR, Mane E, Cassi C, Guerini Rocco E, et al. Revolutionizing Cancer Research: The Impact of Artificial Intelligence in Digital Biobanking. *J Pers Med.*

2023;13.(9)

52. Gandhi H, Kumar K. Artificial Intelligence for the Management of Breast Cancer: An Overview. *Curr Drug Discov Technol.* 2024;21(4):e031123223115.

53. Gandhi Z, Gurram P, Amgai B, Lekkala SP, Lokhandwala A, Manne S, et al. Artificial Intelligence and Lung Cancer: Impact on Improving Patient Outcomes. *Cancers (Basel).* 2023;15.(21)

54. Gao Q, Yang L, Lu M, Jin R, Ye H, Ma T. The artificial intelligence and machine learning in lung cancer immunotherapy. *J Hematol Oncol.* 2023;16(1):55.

55. Govindan B, Sabri MA, Hai A, Banat F, Haija MA. A Review of Advanced Multifunctional Magnetic Nanostructures for Cancer Diagnosis and Therapy Integrated into an Artificial Intelligence Approach. *Pharmaceutics.* 2023;15.(3)

56. Guitton T, Allaupe P, Rabilloud N, Rioux-Leclercq N, Henno S, Turlin B, et al. Artificial Intelligence in Predicting Microsatellite Instability and KRAS, BRAF Mutations from Whole-Slide Images in Colorectal Cancer: A Systematic Review. *Diagnostics (Basel).* 2023;14.(1)

57. Guo J, Hu J, Zheng Y, Zhao S, Ma J. Artificial intelligence: opportunities and challenges in the clinical applications of triple-negative breast cancer. *Br J Cancer.* 2023;128(12):2141-9.

58. Gupta R, Kumar N, Bansal S, Singh S, Sood

N, Gupta S. Artificial Intelligence-driven Digital Cytology-based Cervical Cancer Screening: Is the Time Ripe to Adopt This Disruptive Technology in Resource-constrained Settings? A Literature Review. *J Digit Imaging.* 2023;36(4):1643-52.

59. He C, Xu H, Yuan E, Ye L, Chen Y, Yao J, et al. The accuracy and quality of image-based artificial intelligence for muscle-invasive bladder cancer prediction. *Insights Imaging.* 2024;15(1):185.

60. Hong S, Zhang H. [Research Progress of Artificial Intelligence in Prostate Cancer Diagnosis Application]. *Zhongguo Yi Liao Qi Xie Za Zhi.* 2024;48(4):367-72.

61. Horiuchi Y, Hirasawa T, Fujisaki J. Application of artificial intelligence for diagnosis of early gastric cancer based on magnifying endoscopy with narrow-band imaging. *Clin Endosc.* 2024;57(1):11-7.

62. Ichimasa K, Kudo SE, Misawa M, Takashina Y, Yeoh KG, Miyachi H. Role of the artificial intelligence in the management of T1 colorectal cancer. *Dig Liver Dis.* 2024;56(7):1144-7.

63. Ivanova M, Pescia C, Trapani D, Venetis K, Frascarelli C, Mane E, et al. Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence. *Cancers (Basel).* 2024;16.(11)

64. Jafrasteh F, Farmani A, Mohamadi J. Meticulous research for design of plasmonics sensors for cancer detection and food contaminants analysis via machine learning and

artificial intelligence. *Sci Rep.* 2023;13(1):15349.

65. Jan Z, El Assadi F, Abd-Alrazaq A, Jithesh PV. Artificial Intelligence for the Prediction and Early Diagnosis of Pancreatic Cancer: Scoping Review. *J Med Internet Res.* 2023;25:e44248.

66. Kaneko M, Magouliaitis V, Ramacciotti LS, Raman A, Paralkar D, Chen A, et al. The Novel Green Learning Artificial Intelligence for Prostate Cancer Imaging: A Balanced Alternative to Deep Learning and Radiomics. *Urol Clin North Am.* 2024;51(1):1-13.

67. Kang J, Chowdhry AK, Pugh SL, Park JH. Integrating Artificial Intelligence and Machine Learning Into Cancer Clinical Trials. *Semin Radiat Oncol.* 2023;33(4):386-94.

68. Katayama A, Aoki Y, Watanabe Y, Horiguchi J, Rakha EA, Oyama T. Current status and prospects of artificial intelligence in breast cancer pathology: convolutional neural networks to prospective Vision Transformers. *Int J Clin Oncol.* 2024.

69. Khanagar SB, Alkadi L, Alghilan MA, Kalagi S, Awawdeh M, Bijai LK, et al. Application and Performance of Artificial Intelligence (AI) in Oral Cancer Diagnosis and Prediction Using Histopathological Images: A Systematic Review. *Biomedicines.* 2023;11.(6)

70. Khoraminia F, Fuster S, Kanwal N, Olislagers M, Engan K, van Leenders G, et al. Artificial Intelligence in Digital Pathology for Bladder Cancer: Hype or Hope? A Systematic

Review. *Cancers (Basel).* 2023;15.(18)

71. Khozin S. From organs to algorithms: Redefining cancer classification in the age of artificial intelligence. *Clin Transl Sci.* 2024;17(9):e70001.

72. Kim KW, Huh J, Urooj B, Lee J, Lee J, Lee IS, et al. Artificial Intelligence in Gastric Cancer Imaging With Emphasis on Diagnostic Imaging and Body Morphometry. *J Gastric Cancer.* 2023;23(3):388-99.

73. Kim M, Park T, Oh BY, Kim MJ, Cho BJ, Son IT. Performance reporting design in artificial intelligence studies using image-based TNM staging and prognostic parameters in rectal cancer: a systematic review. *Ann Coloproctol.* 2024;40(1):13-26.

74. Kinkar KK, Fields BKK, Yamashita MW, Varghese BA. Empowering breast cancer diagnosis and radiology practice: advances in artificial intelligence for contrast-enhanced mammography. *Front Radiol.* 2023;3:1326831.

75. Kinoshita T, Komatsu M. Artificial Intelligence in Surgery and Its Potential for Gastric Cancer. *J Gastric Cancer.* 2023;23(3):400-9.

76. Kumar V, Gaddam M, Moustafa A, Iqbal R, Gala D, Shah M, et al. The Utility of Artificial Intelligence in the Diagnosis and Management of Pancreatic Cancer. *Cureus.* 2023;15(11):e49560.

77. Kurozumi S, Ball GR. Research on biomarkers using innovative artificial intelligence systems in breast cancer. *Int J Clin Oncol.* 2024.

78. Kwong JCC, Wu J, Malik S, Khondker A, Gupta N, Bodnariuc N, et al. Predicting non-muscle invasive bladder cancer outcomes using artificial intelligence: a systematic review using APPRAISE-AI. *NPJ Digit Med.* 2024;7(1):98.
79. Ladbury C, Eustace N, Kassardjian A, Amini A, Chen YJ, Wang E, et al. Explainable artificial intelligence analysis of brachytherapy boost receipt in cervical cancer during the COVID-19 era. *Brachytherapy.* 2024;23(3):237-47.
80. Lai B, Fu J, Zhang Q, Deng N, Jiang Q, Peng J. Artificial intelligence in cancer pathology: Challenge to meet increasing demands of precision medicine. *Int J Oncol.* 2023;63.(3)
81. Laurie MA, Zhou SR, Islam MT, Shkolyar E, Xing L, Liao JC. Bladder Cancer and Artificial Intelligence: Emerging Applications. *Urol Clin North Am.* 2024;51(1):63-75.
82. Lee J, Lee H, Chung JW. The Role of Artificial Intelligence in Gastric Cancer: Surgical and Therapeutic Perspectives: A Comprehensive Review. *J Gastric Cancer.* 2023;23(3):375-87.
83. Leo E, Stanzione A, Miele M, Cuocolo R, Sica G, Scaglione M, et al. Artificial Intelligence and Radiomics for Endometrial Cancer MRI: Exploring the Whats, Whys and Hows. *J Clin Med.* 2023;13.(1)
84. Li JW, Wang LM, Ichimasa K, Lin KW, Ngu JC, Ang TL. Use of artificial intelligence in the management of T1 colorectal cancer: a new tool in the arsenal or is deep learning out of its depth?

- Clin Endosc.* 2024;57(1):24-35.
85. Li L, Sun M, Wang J, Wan S. Multi-omics based artificial intelligence for cancer research. *Adv Cancer Res.* 2024;163:303-56.
86. Liang ZC, Sun C, Chen M. [Advances in artificial intelligence-assisted MRI radiomics in the diagnosis and treatment of prostate cancer]. *Zhonghua Nan Ke Xue.* 2024;30(1):60-5.
87. Lin G, Wang X, Ye H, Cao W. Radiomic Models Predict Tumor Microenvironment Using Artificial Intelligence-the Novel Biomarkers in Breast Cancer Immune Microenvironment. *Technol Cancer Res Treat.* 2023;22:15330338231218227.
88. Lindgren Belal S, Frantz S, Minarik D, Enqvist O, Wikström E, Edenbrandt L, et al. Applications of Artificial Intelligence in PSMA PET/CT for Prostate Cancer Imaging. *Semin Nucl Med.* 2024;54(1):141-9.
89. Liu J, Cundy TP, Woon DTS, Desai N, Palaniswami M, Lawrentschuk N. A systematic review on artificial intelligence evaluating PSMA PET scan for intraprostatic cancer. *BJU Int.* 2024.
90. Liu J, Cundy TP, Woon DTS, Lawrentschuk N. A Systematic Review on Artificial Intelligence Evaluating Metastatic Prostatic Cancer and Lymph Nodes on PSMA PET Scans. *Cancers (Basel).* 2024;16.(3)
91. Liu W, Shen N, Zhang L, Wang X, Chen B, Liu Z, et al. Research in the application of artificial intelligence to lung cancer diagnosis. *Front Med*

(Lausanne). 2024;11:1343485.

92. Liu X, Shi J, Li Z, Huang Y, Zhang Z, Zhang C. The Present and Future of Artificial Intelligence in Urological Cancer. *J Clin Med*. 2023;12.(15)

93. Lo Gullo R, Marcus E, Huayanay J, Eskreis-Winkler S, Thakur S, Teuwen J, et al. Artificial Intelligence-Enhanced Breast MRI: Applications in Breast Cancer Primary Treatment Response Assessment and Prediction. *Invest Radiol*. 2024;59(3):230-42.

94. Lococo F, Ghaly G, Chiappetta M, Flamini S, Evangelista J, Bria E, et al. Implementation of Artificial Intelligence in Personalized Prognostic Assessment of Lung Cancer: A Narrative Review. *Cancers (Basel)*. 2024;16.(10)

95. Logullo P, MacCarthy A, Dhiman P, Kirtley S, Ma J, Bullock G, et al. Artificial intelligence in lung cancer diagnostic imaging: a review of the reporting and conduct of research published 2018-2019. *BJR Open*. 2023;5(1):20220033.

96. Lowry KP, Zuiderveld CC. Artificial Intelligence for Breast Cancer Risk Assessment. *Radiol Clin North Am*. 2024;62(4):619-25.

97. Lu H, Zhang J, Cao Y, Wu S, Wei Y, Yin R. Advances in applications of artificial intelligence algorithms for cancer-related miRNA research. *Zhejiang Da Xue Xue Bao Yi Xue Ban*. 2024;53(2):231-43.

98. Lyakhova UA, Lyakhov PA. Systematic review of approaches to detection and classification of skin cancer using artificial

intelligence: Development and prospects. *Comput Biol Med*. 2024;178:108742.

99. M SA, Al-Musawi SG, Al-Alwany AA, Uinarni H, Rasulova I, Rodrigues P, et al. Artificial intelligence in cancer diagnosis: Opportunities and challenges. *Pathol Res Pract*. 2024;253:154996.

100. Ma T, Wang H, Ye Z. Artificial intelligence applications in computed tomography in gastric cancer: a narrative review. *Transl Cancer Res*. 2023;12(9):2379-92.

101. Maida M, Marasco G, Facciorusso A, Shahini E, Sinagra E, Pallio S, et al. Effectiveness and application of artificial intelligence for endoscopic screening of colorectal cancer: the future is now. *Expert Rev Anticancer Ther*. 2023;23(7):719-29.

102. Maki JH, Patel NU, Ulrich EJ, Dhaouadi J, Jones RW. Part I: prostate cancer detection, artificial intelligence for prostate cancer and how we measure diagnostic performance: a comprehensive review. *Curr Probl Diagn Radiol*. 2024;53(5):606-13.

103. Malik S, Wu J, Bodnariuc N, Narayana K, Gupta N, Malik M, et al. Existing trends and applications of artificial intelligence in urothelial cancer A scoping review. *Can Urol Assoc J*. 2023;17(11):E395-e401.

104. Matsubayashi CO, Cheng S, Hulchafo I, Zhang Y, Tada T, Buxbaum JL, et al. Artificial intelligence for gastric cancer in endoscopy: From diagnostic reasoning to market. *Dig Liver Dis*.

- 2024;56(7):1156-63.
105. Maurya R, Chug I, Vudatha V, Palma AM. Applications of spatial transcriptomics and artificial intelligence to develop integrated management of pancreatic cancer. *Adv Cancer Res.* 2024;163:107-36.
106. McCaffrey C, Jahangir C, Murphy C, Burke C, Gallagher WM, Rahman A. Artificial intelligence in digital histopathology for predicting patient prognosis and treatment efficacy in breast cancer. *Expert Rev Mol Diagn.* 2024;24(5):363-77.
107. Mei T, Wang T, Zhou Q. Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients. *Clin Exp Med.* 2024;24(1):60.
108. Merchán Gómez B, Milla Collado L, Rodríguez M. Artificial intelligence in esophageal cancer diagnosis and treatment: where are we now?-a narrative review. *Ann Transl Med.* 2023;11(10):353.
109. Michelutti L, Tel A, Zeppieri M, Ius T, Sembronio S, Robiony M. The Use of Artificial Intelligence Algorithms in the Prognosis and Detection of Lymph Node Involvement in Head and Neck Cancer and Possible Impact in the Development of Personalized Therapeutic Strategy: A Systematic Review. *J Pers Med.* 2023;13(12)
110. Mitchell S, Nikolopoulos M, El-Zarka A, Al-Karawi D, Al-Zaidi S, Ghai A, et al. Artificial Intelligence in Ultrasound Diagnoses of Ovarian

- Cancer: A Systematic Review and Meta-Analysis. *Cancers (Basel).* 2024;16.(2)
111. Mooghal M, Ali MM, Khan W, Ahmer A, Akbar MG, Vohra LM. Advancements in oligometastatic breast cancer: a comprehensive review of current strategies and the role of artificial intelligence. *J Pak Med Assoc.* 2024;74(4 (Supple-4)):S117-s25.
112. Mooghal M, Anjum S, Khan W, Tariq H, Babar A, Vohra LM. Artificial intelligence-powered optimization of KI-67 assessment in breast cancer: enhancing precision and workflow efficiency. a literature review. *J Pak Med Assoc.* 2024;74(4 (Supple-4)):S109-s16.
113. Moroney J, Trivella J, George B, White SB. A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence. *Cancers (Basel).* 2023;15.(10)
114. Morozov A, Taratkin M, Bazarkin A, Rivas JG, Puliatti S, Checucci E, et al. A systematic review and meta-analysis of artificial intelligence diagnostic accuracy in prostate cancer histology identification and grading. *Prostate Cancer Prostatic Dis.* 2023;26(4):681-92.
115. Mukherjee S, Vagha S, Gadkari P. Navigating the Future: A Comprehensive Review of Artificial Intelligence Applications in Gastrointestinal Cancer. *Cureus.* 2024;16(2):e54467.
116. Murmu A, Györfy B. Artificial intelligence methods available for cancer research. *Front Med.*

- 2024.
117. Nagi R, Bibra A, Rakesh N, Patil DJ, Vyas T. Artificial intelligence-integrated optical coherence tomography for screening and early detection of oral cancer. *Gen Dent.* 2024;72(1):46-52.
118. Nduma BN, Nkeonye S, Uwawah TD, Kaur D, Ekhatior C, Ambe S. Use of Artificial Intelligence in the Diagnosis of Colorectal Cancer. *Cureus.* 2024;16(1):e53024.
119. Nicolis O, De Los Angeles D, Taramasco C. A contemporary review of breast cancer risk factors and the role of artificial intelligence. *Front Oncol.* 2024;14:1356014.
120. Noor J, Chaudhry A, Batool S. Microfluidic Technology, Artificial Intelligence, and Biosensors As Advanced Technologies in Cancer Screening: A Review Article. *Cureus.* 2023;15(5):e39634.
121. O'Connor S, Vercell A, Wong D, Yorke J, Fallatah FA, Cave L, et al. The application and use of artificial intelligence in cancer nursing: A systematic review. *Eur J Oncol Nurs.* 2024;68:102510.
122. Obimba DC, Esteva C, Nzouatcham Tsicheu EN, Wong R. Effectiveness of Artificial Intelligence Technologies in Cancer Treatment for Older Adults: A Systematic Review. *J Clin Med.* 2024;13.(17)
123. Patel K, Huang S, Rashid A, Varghese B, Gholamrezanezhad A. A Narrative Review of the Use of Artificial Intelligence in Breast, Lung, and Prostate Cancer. *Life (Basel).* 2023;13.(10)

124. Perez-Lopez R, Ghaffari Laleh N, Mahmood F, Kather JN. A guide to artificial intelligence for cancer researchers. *Nat Rev Cancer.* 2024;24(6):427-41.
125. Pesapane F, Battaglia O, Pellegrino G, Mangione E, Petitto S, Fiol Manna ED, et al. Advances in breast cancer risk modeling: integrating clinics, imaging, pathology and artificial intelligence for personalized risk assessment. *Future Oncol.* 2023;19(38):2547-64.
126. Pesapane F, Giambersio E, Capetti B, Monzani D, Grasso R, Nicosia L, et al. Patients' Perceptions and Attitudes to the Use of Artificial Intelligence in Breast Cancer Diagnosis: A Narrative Review. *Life (Basel).* 2024;14.(4)
127. Pierre K, Gupta M, Raviprasad A, Sadat Razavi SM, Patel A, Peters K, et al. Medical imaging and multimodal artificial intelligence models for streamlining and enhancing cancer care: opportunities and challenges. *Expert Rev Anticancer Ther.* 2023;23(12):1265-79.
128. Pokhriyal SC, Shukla A, Gupta U, Al-Ghuraibawi MMH, Yadav R, Panigrahi K. Application of Artificial Intelligence in Neuroendocrine Lung Cancer Diagnosis and Treatment: A Systematic Review. *Cureus.* 2024;16(5):e61012.
129. Quanyang W, Yao H, Sicong W, Linlin Q, Zewei Z, Donghui H, et al. Artificial intelligence in lung cancer screening: Detection, classification, prediction, and prognosis. *Cancer*

Med. 2024;13(7):e7140.

130. Rai HM, Yoo J, Razaque A. A depth analysis of recent innovations in non-invasive techniques using artificial intelligence approach for cancer prediction. *Med Biol Eng Comput.* 2024.

131. Ramalakshmi K, Srinivasa Raghavan V, Rajagopal S, Krishna Kumari L, Theivanathan G, Kulkarni MB, et al. An extensive analysis of artificial intelligence and segmentation methods transforming cancer recognition in medical imaging. *Biomed Phys Eng Express.* 2024;10.(4)

132. Raza Z, Saqib SU, Bajwa AA. Integrating artificial intelligence techniques for advancements in colorectal cancer management: navigating past and predicting future direction. *J Pak Med Assoc.* 2024;74(4 (Supple-4)):S165-s70.

133. Reddy V, Nafees A, Raman S. Recent advances in artificial intelligence applications for supportive and palliative care in cancer patients. *Curr Opin Support Palliat Care.* 2023;17(2):125-34.

134. Reitsam NG, Enke JS, Vu Trung K, Märkl B, Kather JN. Artificial Intelligence in Colorectal Cancer: From Patient Screening over Tailoring Treatment Decisions to Identification of Novel Biomarkers. *Digestion.* 2024:1-14.

135. Rentiya ZS, Mandal S, Inban P, Vempalli H, Dabbara R, Ali S, et al. Revolutionizing Breast Cancer Detection With Artificial Intelligence (AI) in Radiology and Radiation Oncology: A Systematic Review. *Cureus.* 2024;16(4):e57619.

136. Riaz IB, Harmon S, Chen Z, Naqvi SAA, Cheng L. Applications of Artificial Intelligence in Prostate Cancer Care: A Path to Enhanced Efficiency and Outcomes. *Am Soc Clin Oncol Educ Book.* 2024;44(3):e438516.

137. Riaz IB, Khan MA, Haddad TC. Potential application of artificial intelligence in cancer therapy. *Curr Opin Oncol.* 2024;36(5):437-48.

138. Rodriguez Peñaranda N, Eissa A, Ferretti S, Bianchi G, Di Bari S, Farinha R, et al. Artificial Intelligence in Surgical Training for Kidney Cancer: A Systematic Review of the Literature. *Diagnostics (Basel).* 2023;13.(19)

139. Roisman LC, Kian W, Anoze A, Fuchs V, Spector M, Steiner R, et al. Radiological artificial intelligence - predicting personalized immunotherapy outcomes in lung cancer. *NPJ Precis Oncol.* 2023;7(1):125.

140. Sacca L, Lobaina D, Burgoa S, Lotharius K, Moothedan E, Gilmore N, et al. Promoting Artificial Intelligence for Global Breast Cancer Risk Prediction and Screening in Adult Women: A Scoping Review. *J Clin Med.* 2024;13.(9)

141. Salama V, Godinich B, Geng Y, Humbert-Vidan L, Maule L, Wahid KA, et al. Artificial Intelligence and Machine Learning in Cancer Pain: A Systematic Review. *J Pain Symptom Manage.* 2024.

142. Salinas MP, Sepúlveda J, Hidalgo L, Peirano D, Morel M, Uribe P, et al. A systematic review and meta-analysis of artificial intelligence versus

clinicians for skin cancer diagnosis. *NPJ Digit Med.* 2024;7(1):125.

143. Sanchez K, Kamal K, Manjaly P, Ly S, Mostaghimi A. Clinical Application of Artificial Intelligence for Non-melanoma Skin Cancer. *Curr Treat Options Oncol.* 2023;24(4):373-9.

144. Schreidah CM, Gordon ER, Adeuyan O, Chen C, Lapolla BA, Kent JA, et al. Current status of artificial intelligence methods for skin cancer survival analysis: a scoping review. *Front Med (Lausanne).* 2024;11:1243659.

145. Shaikh K, Mooghal M, Ameen A, Khan W, Zeeshan S, Vohra LM. Transforming breast cancer care: harnessing the power of artificial intelligence and imaging for predicting pathological complete response. a narrative review. *J Pak Med Assoc.* 2024;74(4 (Supple-4)):S43-s8.

146. Sharma A, Kumar R, Yadav G, Garg P. Artificial intelligence in intestinal polyp and colorectal cancer prediction. *Cancer Lett.* 2023;565:216238.

147. Sharma V, Singh A, Chauhan S, Sharma PK, Chaudhary S, Sharma A, et al. Role of Artificial Intelligence in Drug Discovery and Target Identification in Cancer. *Curr Drug Deliv.* 2024;21(6):870-86.

148. Shen H, Jin Z, Chen Q, Zhang L, You J, Zhang S, et al. Image-based artificial intelligence for the prediction of pathological complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer: a systematic review and meta-

analysis. *Radiol Med.* 2024;129(4):598-614.

149. Silva H, Santos GNM, Leite AF, Mesquita CRM, Figueiredo PTS, Stefani CM, et al. The use of artificial intelligence tools in cancer detection compared to the traditional diagnostic imaging methods: An overview of the systematic reviews. *PLoS One.* 2023;18(10):e0292063.

150. Singh SB, Sarrami AH, Gatidis S, Varniab ZS, Chaudhari A, Daldrup-Link HE. Applications of Artificial Intelligence for Pediatric Cancer Imaging. *AJR Am J Roentgenol.* 2024;223(2):e2431076.

151. Soliman A, Li Z, Parwani AV. Artificial intelligence's impact on breast cancer pathology: a literature review. *Diagn Pathol.* 2024;19(1):38.

152. Spadaccini M, Massimi D, Mori Y, Alfarone L, Fugazza A, Maselli R, et al. Artificial Intelligence-Aided Endoscopy and Colorectal Cancer Screening. *Diagnostics (Basel).* 2023;13.(6)

153. Spadaccini M, Troya J, Khalaf K, Facciorusso A, Maselli R, Hann A, et al. Artificial Intelligence-assisted colonoscopy and colorectal cancer screening: Where are we going? *Dig Liver Dis.* 2024;56(7):1148-55.

154. Strzelecki M, Kociołek M, Strąkowska M, Kozłowski M, Grzybowski A, Szczypiński PM. Artificial intelligence in the detection of skin cancer: State of the art. *Clin Dermatol.* 2024;42(3):280-95.

155. Suartz CV, Martinez LM, Cordeiro MD, Flores HA, Kodama S, Cardili L, et al.

Artificial intelligence for predicting response to neoadjuvant chemotherapy for bladder cancer A comprehensive systematic review and meta-analysis. *Can Urol Assoc J.* 2024;18(9):E276-e84.

156. Sufyan M, Shokat Z, Ashfaq UA. Artificial intelligence in cancer diagnosis and therapy: Current status and future perspective. *Comput Biol Med.* 2023;165:107356.

157. Szymaszek P, Tyszka-Czochara M, Ortyl J. Application of Photoactive Compounds in Cancer Theranostics: Review on Recent Trends from Photoactive Chemistry to Artificial Intelligence. *Molecules.* 2024;29.(13)

158. Talyshinskii A, Hameed BMZ, Ravinder PP, Naik N, Randhawa P, Shah M, et al. Catalyzing Precision Medicine: Artificial Intelligence Advancements in Prostate Cancer Diagnosis and Management. *Cancers (Basel).* 2024;16.(10)

159. Thomas J, Ravichandran R, Nag A, Gupta L, Singh M, Panjiyar BK. Advancing Colorectal Cancer Screening: A Comprehensive Systematic Review of Artificial Intelligence (AI)-Assisted Versus Routine Colonoscopy. *Cureus.* 2023;15(9):e45278.

160. Uchikov P, Khalid U, Kraev K, Hristov B, Kraeva M, Tenchev T, et al. Artificial Intelligence in the Diagnosis of Colorectal Cancer: A Literature Review. *Diagnostics (Basel).* 2024;14.(5)

161. van Nijnatten TJA, Payne NR, Hickman SE, Ashrafian H, Gilbert FJ. Overview of trials on artificial intelligence algorithms in breast cancer screening - A roadmap for international

evaluation and implementation. *Eur J Radiol.* 2023;167:111087.

162. Vargas-Cardona HD, Rodriguez-Lopez M, Arrivillaga M, Vergara-Sanchez C, García-Cifuentes JP, Bermúdez PC, et al. Artificial intelligence for cervical cancer screening: Scoping review, 2009-2022. *Int J Gynaecol Obstet.* 2024;165(2):566-78.

163. Viñals R, Jonnalagedda M, Petignat P, Thiran JP, Vassilakos P. Artificial Intelligence-Based Cervical Cancer Screening on Images Taken during Visual Inspection with Acetic Acid: A Systematic Review. *Diagnostics (Basel).* 2023;13.(5)

164. Wang HY, Lin WY, Zhou C, Yang ZA, Kalpana S, Lebowitz MS. Integrating Artificial Intelligence for Advancing Multiple-Cancer Early Detection via Serum Biomarkers: A Narrative Review. *Cancers (Basel).* 2024;16.(5)

165. Wang J, Liu G, Zhou C, Cui X, Wang W, Wang J, et al. Application of artificial intelligence in cancer diagnosis and tumor nanomedicine. *Nanoscale.* 2024;16(30):14213-46.

166. Wang JG. Application and future perspectives of gastric cancer technology based on artificial intelligence. *Tzu Chi Med J.* 2023;35(2):148-51.

167. Wang L, Song Y, Wang H, Zhang X, Wang M, He J, et al. Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade. *Pharmaceuticals (Basel).* 2023;16.(2)

168. Wang Y, Lin W, Zhuang X, Wang X, He Y, Li L, et al. Advances in artificial intelligence for the diagnosis and treatment of ovarian cancer (Review). *Oncol Rep.* 2024;51.(3)
169. Wang Z, Liu Y, Niu X. Application of artificial intelligence for improving early detection and prediction of therapeutic outcomes for gastric cancer in the era of precision oncology. *Semin Cancer Biol.* 2023;93:83-96.
170. Webster EM, Ahsan MD, Perez L, Levi SR, Thomas C, Christos P, et al. Chatbot Artificial Intelligence for Genetic Cancer Risk Assessment and Counseling: A Systematic Review and Meta-Analysis. *JCO Clin Cancer Inform.* 2023;7:e2300123.
171. Weeraratna IN, Kamble AR, Luharia A. Artificial Intelligence Applications for Biomedical Cancer Research: A Review. *Cureus.* 2023;15(11):e48307.
172. Wei ML, Tada M, So A, Torres R. Artificial intelligence and skin cancer. *Front Med (Lausanne).* 2024;11:1331895.
173. Wen D, Soltan A, Trucco E, Matin RN. From data to diagnosis: skin cancer image datasets for artificial intelligence. *Clin Exp Dermatol.* 2024;49(7):675-85.
174. Windsor GO, Bai H, Lourenco AP, Jiao Z. Application of artificial intelligence in predicting lymph node metastasis in breast cancer. *Front Radiol.* 2023;3:928639.
175. Wong EY, Chu TN, Ladi-Seyedian SS.

- Genomics and Artificial Intelligence: Prostate Cancer. *Urol Clin North Am.* 2024;51(1):27-33.
176. Wu X, Li W, Tu H. Big data and artificial intelligence in cancer research. *Trends Cancer.* 2024;10(2):147-60.
177. Xing W, Gao W, Lv X, Zhao Z, Xu X, Wu Z, et al. Artificial intelligence predicts lung cancer radiotherapy response: A meta-analysis. *Artif Intell Med.* 2023;142:102585.
178. Xiong DD, He RQ, Huang ZG, Wu KJ, Mo YY, Liang Y, et al. Global bibliometric mapping of the research trends in artificial intelligence-based digital pathology for lung cancer over the past two decades. *Digit Health.* 2024;10:20552076241277735.
179. Xu M, Chen Z, Zheng J, Zhao Q, Yuan Z. Artificial intelligence-aided optical imaging for cancer theranostics. *Semin Cancer Biol.* 2023;94:62-80.
180. Xu Z, Li W, Dong X, Chen Y, Zhang D, Wang J, et al. Precision medicine in colorectal cancer: Leveraging multi-omics, spatial omics, and artificial intelligence. *Clin Chim Acta.* 2024;559:119686.
181. Yan S, Li J, Wu W. Artificial intelligence in breast cancer: application and future perspectives. *J Cancer Res Clin Oncol.* 2023;149(17):16179-90.
182. Yang J, Huang J, Han D, Ma X. Artificial Intelligence Applications in the Treatment of Colorectal Cancer: A Narrative Review. *Clin Med Insights Oncol.* 2024;18:11795549231220320.

183. Yao X, Kumar MV, Su E, Flores Miranda A, Saha A, Sussman J. Evaluating the efficacy of artificial intelligence tools for the automation of systematic reviews in cancer research: A systematic review. *Cancer Epidemiol.* 2024;88:102511.
184. Yao X, Zhou Z, Mao S, Cao J, Li H. Lymph node metastasis detection using artificial intelligence in T1 colorectal cancer: A comprehensive systematic review. *J Surg Oncol.* 2024.
185. Yin Z, Yao C, Zhang L, Qi S. Application of artificial intelligence in diagnosis and treatment of colorectal cancer: A novel Prospect. *Front Med (Lausanne).* 2023;10:1128084.
186. Young E, Edwards L, Singh R. The Role of Artificial Intelligence in Colorectal Cancer Screening: Lesion Detection and Lesion Characterization. *Cancers (Basel).* 2023;15.(21)
187. Yousif M, Pantanowitz L. Artificial Intelligence-Enabled Gastric Cancer Interpretations: Are We There yet? *Surg Pathol Clin.* 2023;16(4):673-86.
188. Zadeh Shirazi A, Tofighi M, Gharavi A, Gomez GA. The Application of Artificial Intelligence to Cancer Research: A Comprehensive Guide. *Technol Cancer Res Treat.* 2024;23:15330338241250324.
189. Zha Y, Xue C, Liu Y, Ni J, De La Fuente JM, Cui D. Artificial intelligence in theranostics of gastric cancer, a review. *Med Rev (2021).*

- 2023;3(3):214-29.
190. Zhang C, Xu J, Tang R, Yang J, Wang W, Yu X, et al. Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment. *J Hematol Oncol.* 2023;16(1):114.
191. Zhang J, Wu J, Zhou XS, Shi F, Shen D. Recent advancements in artificial intelligence for breast cancer: Image augmentation, segmentation, diagnosis, and prognosis approaches. *Semin Cancer Biol.* 2023;96:11-25.
192. Zhang YP, Zhang XY, Cheng YT, Li B, Teng XZ, Zhang J, et al. Artificial intelligence-driven radiomics study in cancer: the role of feature engineering and modeling. *Mil Med Res.* 2023;10(1):22.
193. Zhao G, Chen X, Zhu M, Liu Y, Wang Y. Exploring the application and future outlook of Artificial intelligence in pancreatic cancer. *Front Oncol.* 2024;14:1345810.
194. Zhao LT, Liu ZY, Xie WF, Shao LZ, Lu J, Tian J, et al. What benefit can be obtained from magnetic resonance imaging diagnosis with artificial intelligence in prostate cancer compared with clinical assessments? *Mil Med Res.* 2023;10(1):29.
195. Zhao M, Li Z, Gu X, Yang X, Gao Z, Wang S, et al. The role of radiomics for predicting of lymphovascular space invasion in cervical cancer patients based on artificial intelligence: a systematic review and meta-analysis. *J Gynecol Oncol.* 2024.
196. Zhong J, Shi J, Amundadottir LT. Artificial intelligence and improved early detection

- for pancreatic cancer. *Innovation (Camb)*. 2023;4(4):100457.
197. Zhu L, Pan J, Mou W, Deng L, Zhu Y, Wang Y, et al. Harnessing artificial intelligence for prostate cancer management. *Cell Rep Med*. 2024;5(4):101506.
198. Ghadery M, Taslimi F, Hamel Darbandi M, Shabbak A, Ranjbarian T, Hamel Darbandi M, et al. A Narration of Orthopedic Surgery Experiences in COVID-19 Patients: Case Series of Early Complications . *Updates in Emergency Medicine*. 2022;2(1):34-9.
199. Mohammadi AT, Sanjarian S, Tehrany PM, Khorram R, Vafadar R, Mohseni H, et al. Cutting-Edge Advances in Surgery: Nobel Sciences; 2023.
200. Rigi A, Ghanbarzadeh E, Pourmirbabaei S, Soleymanpour A, Taslimi F, Shabbak A, et al. Clinical and Demographic Features of Burn Patients in Rasht . *Updates in Emergency Medicine*. 2022;2(1):60-6.
201. Shabbak A, Masoumkhani F, Fallah A, Amani-Beni R, Mohammadpour H, Shahbazi T, et al. 3D Printing for Cardiovascular Surgery and Intervention: A Review Article. *Curr Probl Cardiol*. 2024;49(1 Pt B):102086.
202. Farrokhi M, Taheri F, Adibnia E, Mehrtabar S, Rassaf Z, Toyserkani SH, et al. The AI Diagnostician: Improving Medical Diagnosis with Artificial Intelligence. *Kindle*. 2024;4(1):1-219.
203. Motavaselian M, Bayati F, Amani-Beni R, Khalaji A, Haghverdi S, Abdollahi Z, et al.

- Diagnostic performance of magnetic resonance imaging for detection of acute appendicitis in pregnant women; a systematic review and meta-analysis. *Archives of academic emergency medicine*. 2022;10.(1)
204. Motavaselian M, Farrokhi M, Khouzani PJ, Fard AM, Daeizadeh F, Pourrahimi M, et al. Diagnostic Performance of Ultrasonography for Identification of Small Bowel Obstruction; a Systematic Review and Meta-analysis. *Archives of Academic Emergency Medicine*. 2024;12.(1)
205. Rahmani E, Fard AM, Baghsheikhi H, Hosseini Z, Mashaollahi A, Atighi J, et al. Role of Selenium in Pathogenesis and Treatment of the Autoimmune Diseases. *Kindle*. 2022;2(1):1-131.
206. Shamabadi A, Karimi H, Arabzadeh Bahri R, Motavaselian M, Akhondzadeh S. Emerging drugs for the treatment of irritability associated with autism spectrum disorder. *Expert Opinion on Emerging Drugs*. 2024;29(1):45-56.
207. Farrokhi M, Taheri F, Tabatabaei-Nodushan SM-H. Prevalence of Idiopathic Scoliosis in Iranian School Students: A Systematic Review and Meta-analysis. *Journal of Reviews in Medical Sciences*. 2022;2(1):1-9.
208. Dehghani M, Ravanbod H, Ardakani MP, Nodushan MHT, Dehghani S, Rahmani M. Surgical versus conservative management of distal radius fracture with coronal shift; a randomized controlled trial. *International Journal of Burns and Trauma*. 2022;12(2):66.

209. Etemadifar MR, Andalib A, Rahimian A, Nodushan SMHT. Cobalt chromium-Titanium rods versus Titanium-Titanium rods for treatment of adolescent idiopathic scoliosis; which type of rod has better postoperative outcomes? *Revista da Associação Médica Brasileira*. 2018;64(12):1085-90.
210. Hatami H, Mohebbi M, Tabatabaei Nodoushan MH. Validity index of ultrasonography findings, fine needle aspiration cytology, PSA and DRE in patients suspicious for prostate cancer. *Researcher Bulletin of Medical Sciences*. 2024;28(1):e2.
211. Hedayat A, Soltani AE, Hakiminezhad M, Zareian F, Saneian M, Moradmand M, et al. Efficacy and safety of Apixaban for the prevention of thrombosis in arteriovenous grafts. *European Journal of Translational Myology*. 2024;34.(1)
212. Jafari R, Cegolon L, Dehghanpoor F, Javanbakht M, Tabatabaei SMH. Typical Covid-19 case with primary pneumomediastinum in a 37 year old male. *Radiology Case Reports*. 2021;16(8):2286-8.
213. Kamani F, Ghorbani H, Mahmoudabadi FD, Chavoshinejad M, Hakiminezhad M, Zareifar N, et al. Modified Lichtenstein hernioplasty with concomitant tissue repair: a retrospective study on postoperative chronic pain. *BMC Surg*. 2024;24(1):222.
214. Saadat SH, Izadi M, Jonaidi Jafari N, Abolghasemi H, Jamalimoghadamsiyahkali S,

- Jamalian A, et al. Fear and Panic of COVID-19. *International Journal of Travel Medicine and Global Health*. 2020;8(3):91-2.
215. Tahririan MA, Nodushan SMHT, Farrokhi M. Chronic recurrent multifocal osteomyelitis in a 3.5-year-old boy. *Journal of Research in Medical Sciences*. 2021;26(1):32.
216. Farrokhi M, Khouzani SJ, Farrokhi M, Jalayeri H, Faranoush P, Babaei M, et al. *Artificial Intelligence and Deep Learning for Screening and Risk Assessment of Cancers*. Kindle. 2024;4(1):1-140.
217. Farrokhi M, Taheri F, Bayat Z, Damiri M, Farrokhi M, Ghadirzadeh E, et al. *Role of Lifestyle Medicine in the Prevention and Treatment of Diseases*. Kindle. 2024;4(1):1-219.
218. Farrokhi M, Taheri F, Farrokhi M, Emtiazi N, Talebi M, Akbari A, et al. *Human and AI: Collaborative Medicine in the Age of Technology*. Kindle. 2024;4(1):1-160.
219. Farrokhi M, Taheri F, Farrokhi M, Heydari Z, Darbani R, Salbi M, et al. *Advancements and Innovations in Cancer Management: A Comprehensive Perspective*. Kindle. 2024;4(1):1-161.
220. Farrokhi M, Taheri F, Farrokhi M, Moeini A, Tooyserkani SH, Shahali A, et al. *Anti-Aging Strategies to Prevent Diseases: Promoting Longevity and Optimal Health*. Kindle. 2024;4(1):1-194.
221. Farrokhi M, Taheri F, Farrokhi M, Tosi

YEK, Ghadirzadeh E, Bagheri M, et al. Nanomedicine: Technologies and Applications. Kindle. 2024;4(1):1-196.

222. Farrokhi M, Taheri F, Moeini A, Farrokhi M, Alireza MZS, Farahmandsadr M, et al. Artificial Intelligence for Remote Patient Monitoring: Advancements, Applications, and Challenges. Kindle. 2024;4(1):1-261.

223. Farrokhi M, Taheri F, Moeini A, Farrokhi M, Khouzani PJ, Ghadirzadeh E, et al. Artificial Intelligence for Drug Development, Personalized Prescriptions, and Adverse Event Prediction. Kindle. 2024;4(1):1-180.

224. Karimian S, Taheri F, Farrokhi M, Farrokhi M, Bayat Z, Zadeh SAM, et al. Digital Health and Wearable Technologies. Kindle. 2024;4(1):1-240.

225. Taheri F, Farrokhi M, Rajabloo Y, Razavi N, Shirdel E, Hooshidar MH, et al. Complementary and alternative medicine (CAM). Kindle. 2024;4(1):1-193.

226. Goncalves Leite Rocco P, Reategui-Rivera CM, Finkelstein J. Telemedicine Applications for Cancer Rehabilitation: Scoping Review. JMIR Cancer. 2024;10:e56969.

227. Mashoudy KD, Perez SM, Nouri K. From diagnosis to intervention: a review of telemedicine's role in skin cancer care. Arch Dermatol Res. 2024;316(5):139.

228. Agochukwu NQ, Skolarus TA, Wittmann D. Telemedicine and prostate cancer survivorship: a narrative review. Mhealth. 2018;4:45.

229. Khoury ZH, Sultan AS. Tele-Oral Oncology: Reinvigorating Telemedicine in Oral Cancer Care. J Cancer Allied Spec. 2020;6(1):e335.

230. Shalowitz DI, Moore CJ. Telemedicine and Gynecologic Cancer Care. Obstet Gynecol Clin North Am. 2020;47(2):271-85.

231. Chan RJ, Crichton M, Crawford-Williams F, Agbejule OA, Yu K, Hart NH, et al. The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews. Ann Oncol. 2021;32(12):1552-70.

232. Almubarak H. The Potential Role of Telemedicine in Early Detection of Oral Cancer: A Literature Review. J Pharm Bioallied Sci. 2022;14(Suppl 1):S19-s23.

233. Deo SV, Pramanik R, Chaturvedi M, Nath A, Ghosh J, Das Majumdar SK, et al. Telemedicine and cancer care in India: promises, opportunities and caveats. Future Sci OA. 2022;8(9):Fso821.

234. Garavand A, Aslani N, Behmanesh A, Shams R. Telemedicine in lung cancer during COVID-19 outbreak: A scoping review. J Educ Health Promot. 2022;11:348.

235. Jakeman M, Khaw R, Zack-Williams S, Brackley P. Implementation of a telemedicine service to provide skin cancer care in a tertiary plastic surgery unit during COVID-19 - a comprehensive review. J Plast Reconstr Aesthet Surg. 2022;75(9):3608-15.

236. Mostafaei A, Sadeghi-Ghyassi F, Kabiri

N, Hajebrahimi S. Experiences of patients and providers while using telemedicine in cancer care during COVID-19 pandemic: a systematic review and meta-synthesis of qualitative literature. *Support Care Cancer*. 2022;30(12):10483-94.

237. Pang NQ, Lau J, Fong SY, Wong CY, Tan KK. Telemedicine Acceptance Among Older Adult Patients With Cancer: Scoping Review. *J Med Internet Res*. 2022;24(3):e28724.

238. Tang M, Reddy A. Telemedicine and Its Past, Present, and Future Roles in Providing Palliative Care to Advanced Cancer Patients. *Cancers (Basel)*. 2022;14.(8)

239. Uemoto Y, Yamanaka T, Kataoka Y, Wada Y, Aoyama Y, Kizawa R, et al. Efficacy of Telemedicine Using Videoconferencing Systems in Outpatient Care for Patients With Cancer: A Systematic Review and Meta-Analysis. *JCO Clin Cancer Inform*. 2022;6:e2200084.

240. West HJ, Barzi A, Wong D. Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0? *Curr Oncol Rep*. 2022;24(12):1843-50.

241. Giustiniani A, Danesin L, Pezzetta R, Masina F, Oliva G, Arcara G, et al. Use of Telemedicine to Improve Cognitive Functions and Psychological Well-Being in Patients with Breast Cancer: A Systematic Review of the Current Literature. *Cancers (Basel)*. 2023;15.(4)

242. Davidoff C, Cheville A. Telemedicine in Cancer Rehabilitation: Applications and

Opportunities Across the Cancer Care Continuum. *Am J Phys Med Rehabil*. 2024;103(3S Suppl 1):S52-s7.

243. Doshi SD, Bange EM, Daly B, Kuperman G, Panageas KS, Morris MJ. Telemedicine and Cancer Care: Barriers and Strategies to Optimize Delivery. *Cancer J*. 2024;30(1):8-15.

244. Ren L, Chen M, Jiang H, Wang Y, Xia L, Dong C. Perceptions of adult patients with cancer towards telemedicine: A qualitative meta-synthesis. *Asia Pac J Oncol Nurs*. 2024;11(2):100360.

245. Toni E, Ayatollahi H. An insight into the use of telemedicine technology for cancer patients during the Covid-19 pandemic: a scoping review. *BMC Med Inform Decis Mak*. 2024;24(1):104.

246. Silver FH, Mesica A, Gonzalez-Mercedes M, Deshmukh T. Identification of Cancerous Skin Lesions Using Vibrational Optical Coherence Tomography (VOCT): Use of VOCT in Conjunction with Machine Learning to Diagnose Skin Cancer Remotely Using Telemedicine. *Cancers (Basel)*. 2022;15.(1)

247. Cascella M, Scarpati G, Bignami EG, Cuomo A, Vittori A, Di Gennaro P, et al. Utilizing an artificial intelligence framework (conditional generative adversarial network) to enhance telemedicine strategies for cancer pain management. *J Anesth Analg Crit Care*. 2023;3(1):19.

248. Kabukye JK, Namugga J, Mpamani CJ,

- Katumba A, Nakatumba-Nabende J, Nabuuma H, et al. Implementing Smartphone-Based Telemedicine for Cervical Cancer Screening in Uganda: Qualitative Study of Stakeholders' Perceptions. *J Med Internet Res.* 2023;25:e45132.
249. Cui F, Zhang X, He X, Liu D, Shi J, Ye M, et al. Clinical applications of telemedicine services using a regional telemedicine platform for cancer treatment: a cross-sectional study. *BMC Cancer.* 2024;24(1):808.
250. Tao W, Yu X, Shao J, Li R, Li W. Telemedicine-Enhanced Lung Cancer Screening Using Mobile Computed Tomography Unit with Remote Artificial Intelligence Assistance in Underserved Communities: Initial Results of a Population Cohort Study in Western China. *Telemed J E Health.* 2024;30(6):e1695-e704.
251. von Itzstein MS, Gwin ME, Gupta A, Gerber DE. Telemedicine and Cancer Clinical Research: Opportunities for Transformation. *Cancer J.* 2024;30(1):22-6.
252. Bansal V, Pingnot E, 3rd, Huh B, Javed S. Trends of opioid prescription in cancer patients utilizing telemedicine: a retrospective study. *Pain Manag.* 2023;13(9):509-17.
253. Calton BA, Nouri S, Davila C, Kotwal A, Zapata C, Bischoff KE. Strategies to Make Telemedicine a Friend, Not a Foe, in the Provision of Accessible and Equitable Cancer Care. *Cancers (Basel).* 2023;15.(21)
254. Casà C, Corvari B, Cellini F, Cornacchione

- P, D'Aviero A, Reina S, et al. KIT 1 (Keep in Touch) Project-Televisits for Cancer Patients during Italian Lockdown for COVID-19 Pandemic: The Real-World Experience of Establishing a Telemedicine System. *Healthcare (Basel).* 2023;11.(13)
255. Chimonas S, Lipitz-Snyderman A, Spiegelhoff Z, Chakraborty N, Seier K, White C, et al. Persistence of Telemedicine Usage for Breast and Prostate Cancer after the Peak of the COVID-19 Pandemic. *Cancers (Basel).* 2023;15.(20)
256. Guadamuz JS, Wang X, Royce TJ, Calip GS. Sociodemographic Inequities in Telemedicine Use Among US Patients Initiating Treatment in Community Cancer Centers During the Ongoing COVID-19 Pandemic, 2020-2022. *JCO Oncol Pract.* 2023;19(12):1206-14.
257. Ha DM, Comer A, Dollar B, Bedoy R, Ford M, Gozansky WS, et al. Telemedicine-based inspiratory muscle training and walking promotion with lung cancer survivors following curative intent therapy: a parallel-group pilot randomized trial. *Support Care Cancer.* 2023;31(9):546.
258. Larbre V, Romain-Scelle N, Reymond P, Ladjouzi Y, Herledan C, Caffin AG, et al. Cancer outpatients during the COVID-19 pandemic: what Oncoral has to teach us about medical drug use and the perception of telemedicine. *J Cancer Res Clin Oncol.* 2023;149(14):13301-10.
259. Ma Z, Shi Y, Yao S, Lu N, Cheng F.

Effectiveness of telemedicine-based psychosocial intervention for breast cancer patients: a systematic review and meta-analysis. *Support Care Cancer*. 2023;31(10):595.

260. Shusted CS, Juon HS, Ruane B, Till B, Zeigler-Johnson C, McIntire RK, et al. Individual- and neighborhood-level characteristics of lung cancer screening participants undergoing telemedicine shared decision making. *BMC Health Serv Res*. 2023;23(1):1179.

261. Bange EM, Li Y, Kumar P, Doucette A, Gabriel P, Parikh R, et al. The association between telemedicine, advance care planning, and unplanned hospitalizations among high-risk patients with cancer. *Cancer*. 2024;130(4):636-44.

262. Boehm L, Jalbuena T, Haskins A, Holt C, Speckhart SA. Preference of Young Adult Cancer Survivors for In-Person Versus Telemedicine Cancer Survivorship Visits. *J Adolesc Young Adult Oncol*. 2024;13(3):573-6.

263. Chiang AC. Telemedicine and Cancer: Shifting a Paradigm of Care. *Cancer J*. 2024;30(1):1.

264. Dhawale TM, Bhat RS, Johnson PC, Srikonda S, Lau-Min KS, Boateng K, et al. Telemedicine-based serious illness conversations, healthcare utilization, and end of life care among patients with advanced lung cancer. *Oncologist*. 2024.

265. Endo Y, Woldesenbet S, Tsilimigras DI, Munir MM, Khalil M, Khan MMM, et al. Effect of telemedicine use on medical spending and health care utilization among patients

with gastrointestinal cancer. *J Gastrointest Surg*. 2024;28(9):1456-62.

266. Farmaki A, Schmitt T, Natsiavas P. Exploring User Views on Telemedicine to Support Cancer Patients: Insights from Focus Group Discussions in the Context of the eCAN Joint Action. *Stud Health Technol Inform*. 2024;316:55-6.

267. Freeman JQ, Khwaja A, Zhao F, Nanda R, Olopade OI, Huo D. Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis. *Telemed J E Health*. 2024;30(3):651-63.

268. Freeman JQ, Zhao F, Howard FM, Nanda R, Olopade OI, Huo D. Assessing the Relationship Between Neighborhood Socioeconomic Disadvantage and Telemedicine Use Among Patients With Breast Cancer and Examining Differential Provisions of Oncology Services Between Telehealth and In-Person Visits: Quantitative Study. *JMIR Cancer*. 2024;10:e55438.

269. Gadzinski AJ, Dwyer EM, Reynolds J, Stewart B, Abarro I, Wolff EM, et al. Interstate Telemedicine for Urologic Cancer Care. *J Urol*. 2024;211(1):55-62.

270. Guo J, Xu X, Liu C, Wang Y, Chen Y. Perspectives of telemedicine-based services among family caregivers of patients with end-of-life cancer: a qualitative study in mainland China. *BMC Palliat Care*. 2024;23(1):16.

271. Hung TKW, Verdini NP, Gilliland JL, Chimonas S, Cracchiolo JR, Li Y, et al. When Is Telemedicine Appropriate in the Management of Head and Neck Cancer? A Mixed-Methods Assessment Among Patients and Physicians. *JCO Oncol Pract.* 2024;20(8):1091-102.
272. Lee M, Tsai MH, Tillewein H, Luckey GS. Rural-Urban Disparities in Telemedicine Use Among U.S. Adults with Cancer. *Telemed J E Health.* 2024;30(6):1539-48.
273. Leong D, Ng A, Chang P, Zheng J, Wilson R, Chen ME, et al. Telemedicine impact on patient disparities and physician practice patterns in cancer rehabilitation: A multicenter retrospective study. *Pm r.* 2024.
274. Lichtenstein MRL, Levit LA, Schenkel C, Kirkwood K, Fashoyin-Aje LA, Bruinooge SS, et al. Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials. *Oncologist.* 2024;29(4):356-63.
275. Mali SB. Role of telemedicine in head neck cancer. *Oral Oncol.* 2024;151:106746.
276. Nasir KS, Badar F, Yusuf MA. Using Telemedicine to Care for Patients with Breast Cancer: A Natural Quasi-Experimental Study. *J Cancer Allied Spec.* 2024;10(2):679.
277. Ng AH, Tennison J, Fu JB, Gupta E, Lu Z, Bruera E. Predictors of a Preference for Telemedicine Virtual Visits in Patients Undergoing Cancer Rehabilitation. *Am J Phys Med*

- Rehabil.* 2024;103(9):835-9.
278. Okoye F, Gadzinski AJ, Sekar R, Abarro I, Grivas P, Tykodi SS, et al. Telemedicine for Multidisciplinary Urologic Cancer Care: A Prospective Single Institution Study. *Clin Genitourin Cancer.* 2024;22(3):102058.
279. Quan H, Wang H, Yang Y, Yu H. The Safety and Effectiveness of Telemedicine for Cancer-Related Colostomy Care in the Early Stage of Discharge: A Prospective, Randomized, Single-Center Study. *Telemed Rep.* 2024;5(1):212-8.
280. Singh N, Tanwar P, Singhal S, Mohan T, Mittal C, Mangal S, et al. Novel Strategy of Training the Accredited Social Health Activists via Application-Based Telemedicine for Cervical Cancer Screening by Human Papillomavirus Self-Sampling: The TRACK Study. *JCO Glob Oncol.* 2024;10:e2400158.
281. Smith AJB, Gleason EG, Andriani L, Heintz J, Ko EM. Variation in telemedicine usage in gynecologic cancer: Are we widening or narrowing disparities? *Gynecol Oncol.* 2024;184:160-7.

Proof